EP3930747A1 - Association d'immunothérapies pour le traitement du cancer - Google Patents

Association d'immunothérapies pour le traitement du cancer

Info

Publication number
EP3930747A1
EP3930747A1 EP20763489.0A EP20763489A EP3930747A1 EP 3930747 A1 EP3930747 A1 EP 3930747A1 EP 20763489 A EP20763489 A EP 20763489A EP 3930747 A1 EP3930747 A1 EP 3930747A1
Authority
EP
European Patent Office
Prior art keywords
cancer
vaccine
cells
dna vaccine
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20763489.0A
Other languages
German (de)
English (en)
Other versions
EP3930747A4 (fr
Inventor
Jonathan Zalevsky
Agnete Brunsvik Fredriksen
Mads Axelsen
Karoline SCHJETNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nykode Therapeutics ASA
Nektar Therapeutics
Original Assignee
Vaccibody AS
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccibody AS, Nektar Therapeutics filed Critical Vaccibody AS
Publication of EP3930747A1 publication Critical patent/EP3930747A1/fr
Publication of EP3930747A4 publication Critical patent/EP3930747A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Definitions

  • cancer immunotherapy and in a particular aspect, cancer immunotherapy, and involves the treatment of an individual having cancer by administering to the individual an anticancer vaccine such as a DNA neoantigen vaccine, in combination with a T cell expander, optionally further combined with a checkpoint inhibitor.
  • an anticancer vaccine such as a DNA neoantigen vaccine
  • Cancer is a genetic disorder that results from genetic or epigenetic alternations in the somatic cells and represents one of the most deadly diseases in the developed world.
  • Tumorigenesis in humans is a multistep process which involves various genetic or epigenetic changes that ultimately drive the malignant transformation of normal cells. While our understanding of mechanisms leading to malignancy continues to make enormous strides, the complexity of the processes that drive the development, growth and spread of cancer make the development of new and effective treatments particularly challenging.
  • Therapeutic cancer vaccines represent a class of substances that work by stimulating or restoring a subject’s immune system’s ability to fight infections and disease.
  • Therapeutic vaccines as opposed to preventative or prophylactic vaccines, are used to treat an existing cancer by boosting the body’s natural immune response against the cancer and represent a type of immunotherapy.
  • Cancer treatment vaccines are designed to activate cytotoxic T cells and direct them to recognize and act against specific types of cancer or to induce production of antibodies that bind to molecules on the surface of cancer cells.
  • tumor-associated antigens are antigens that are expressed at low levels in normal tissues, but are expressed at much higher levels in tumor tissue.
  • producing effective therapeutic vaccines that bind to tumor-associated antigens has proven to be a challenging endeavor, at least in part, because the vaccine intervention must combat the body’s immune system that is restrained by mechanisms that work to sustain the cancer.
  • therapeutic approaches based upon tumor- associated antigen-based vaccines may also lead to toxicities due to normal cell destruction.
  • a therapeutic cancer vaccine must not only stimulate a specific immune response against an intended target, but must also be powerful enough to overcome the barriers that cancer cells utilize to protect themselves from attack by killer T cells.
  • Therapeutic vaccines have been evaluated, for example, in patients with breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, and renal cancer (Melero, I., et al, Nat Rev Clin Oncol, 2014, 11 (9), 509-524), although such therapeutic anticancer vaccines have met with limited success.
  • neoantigen-based DNA cancer vaccine a compound effective to stimulate/expand production of T cells (i.e., effector T cells,“a T cell expander”).
  • the disclosure provides a method for treating a subject having cancer, the method comprising administering to the subject, (i) an anticancer DNA vaccine directed to a plurality of neoepitopes from tumor neoantigens, (ii) a compound effective to stimulate/expand production of T cells, and optionally, (iii) a checkpoint inhibitor.
  • the neoepitopes comprised in the DNA vaccine are presented to the immune system as a dimeric protein called a vaccibody (to be described in greater detail herein), i.e., in such embodiments, the vaccine is referred to as a vaccibody DNA vaccine.
  • a vaccibody DNA vaccine i.e., in such embodiments, the vaccine is referred to as a vaccibody DNA vaccine.
  • WO 2004/076489 describes dimeric proteins called vaccibodies in detail.
  • Targeting units are described in detail in WO 2011/161244.
  • the neoantigen-based DNA cancer vaccine comprises an immunologically effective amount of a DNA polynucleotide comprising a nucleotide sequence encoding (i) a targeting unit, (ii) a dimerization unit, (iii) a first linker and (iv) an antigenic unit, where the antigenic unit comprises n-1 antigenic subunits (where n is an integer of from about 3 to 50), each subunit comprising at least a part of a cancer neoepitope sequence and a second linker, and further comprising a final cancer neoepitope sequence.
  • the neoantigen-based DNA cancer vaccine comprises an immunologically effective amount of a DNA polynucleotide comprising a nucleotide sequence encoding an antigenic unit.
  • the antigenic unit comprises n-1 antigenic subunits, where each subunit comprises at least a part of a cancer neoepitope sequence and a linker, and further comprises a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50.
  • the vaccine is a vaccibody DNA vaccine comprising from 10 to 50 neoepitopes, or from 15 to 40 neoepitopes, or from 10 to 30 neoepitopes, or from 10-20 neoepitopes.
  • the vaccine comprises a DNA polynucleotide comprising a nucleotide sequence encoding an antigenic unit as described above, wherein the linker is an amino acid linker.
  • linkers include, for example, glycine/serine-rich linkers. Further exemplary linkers include, for example, the linkers identified as SEQ ID NO:67-76.
  • Exemplary mouse neoantigen-based DNA cancer vaccines comprising
  • VB10.NEO pDNA constructs VB4011 and VB4061, are described in the supporting examples.
  • the vaccine comprises a DNA
  • the vaccine comprises a DNA pVBlO.NEO plasmid backbone sequence as provided in FIG. 12.
  • the T cell expander when administered in combination with the neoantigen-based DNA cancer vaccine is effective to enhance specific clonal T cell expansion to vaccine epitopes over that achieved upon administration of the neoantigen-based DNA cancer vaccine in the absence of the T cell expander to a degree that is greater than additive.
  • the T cell expander is a prodrug of an interleukin-2 (e.g., aldesleukin, des-alanyl-1, serine-125 human interleukin-2), wherein the interleukin-2 is modified by releasable covalent attachment of multiple polyethylene glycol moieties.
  • the T cell expander is an interleukin-2 receptor beta (IL-2R_ ) selective agonist.
  • the T cell expander is an IL-2R]3-selective agonist composition, multi(2,7-(bis-methoxyPEG-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)interleukin-2 (also referred to herein as“RSLAIL-2”), comprising compounds of Formula (I),
  • IL-2 is interleukin-2 (such as, for example, aldesleukin)
  • -NH-IL-2 represents an amino group of interleukin-2
  • each integer (n) has a value from about 200-300; or pharmaceutically acceptable salt forms thereof.
  • “n” in each of the polyethylene glycol chains is about 227 (i.e., where each polyethylene glycol chain extending from the central fluorenyl core has a weight average molecular weight of about 10,000 daltons, such that the weight average molecular weight of each overall branched PEG moiety is about 20,000 daltons).
  • the T cell expander is (2,7-(bis- methoxyPEGiok d -carboxyamide)(9h-fluorene-9-yl)methyl N-carbamate)6 avg interleukin-2.
  • numbers of neoantigen-based DNA cancer vaccine-induced T cells in the tumor are increased in number over such T cells determined upon following administration of one or more doses of the neoantigen-based DNA cancer vaccine alone, when evaluated in either a clinical or a preclinical setting.
  • the cancer is a solid cancer.
  • the cancer is selected from, for example, the group consisting of breast cancer, ovarian cancer, colon cancer, prostate cancer, bone cancer, colorectal cancer, gastric cancer, lymphoma, malignant melanoma, liver cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, thyroid cancers, kidney cancer, e.g., renal cell carcinoma, cancer of the bile duct, cancer of the head and neck (e.g., squamous cell carcinomas of the head and neck), brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer (e.g., urothelial carcinoma), esophageal cancer, Hodgkin's disease and adrenocortical cancer, among others.
  • SCLC small cell lung cancer
  • NSCLC non-small cell lung cancer
  • pancreatic cancer thyroid cancers
  • kidney cancer e.g., renal cell carcinoma, cancer of the bile duct, cancer of the head and neck (e.g., s
  • the cancer is selected from locally advanced or metastatic melanoma, non-small cell lung cancer, clear renal cell carcinoma, urothelial cancer, and squamous cell carcinoma of the head and neck.
  • the cancer is melanoma or colon cancer.
  • the neoantigen-based DNA cancer vaccine and the T cell expander, and optionally a checkpoint inhibitor may be administered concurrently or sequentially, and in any order, and via the same and/or different routes of administration. More particularly, the therapeutic components of the combination therapy may each be administered on the same day, on different days, or, a mixture of both (two immunotherapeutic components administered on the same day and one immunotherapeutic component administered on a different day).
  • treatment may comprise a single cycle of therapy, or may comprise multiple cycles, including one or more doses of each of the neoantigen-based DNA cancer vaccine, the T cell expander, and the optional checkpoint inhibitor.
  • treatment may comprise a mixture of single cycle and multiple cycles, such as, for example at least one of the neoantigen-based DNA cancer vaccine, the T cell expander, and the optional checkpoint inhibitor is administered for a single cycle and one or more of the neoantigen- based DNA cancer vaccine, the T cell expander, and the optional checkpoint inhibitor is administered for multiple cycles.
  • the T cell expander is administered following administration of the neoantigen-based DNA cancer vaccine.
  • the T cell expander is administered following the neoantigen-based DNA cancer vaccine induction phase, wherein such induction phase may span one or more administrations of the vaccine, e.g., 1, 2, 3, 4 or more vaccinations over a given time period.
  • the time following the induction phase is a time, following one or more vaccinations, at which the neoepitope- specific T cell response has substantially levelled off, that is, is no longer significantly increasing.
  • such time is within a time frame in which the neoepitope-specific T cell response has reached its maximum, or is within +25% of its maximum, or is within + 15% of its maximum, or is within about + 10% of its maximum.
  • the T cell expander may be administered within about 3-20 days following the last vaccination of the induction period, or within about 3-15 days following the last vaccination of the induction period, or within about 7-20 days following the last vaccination of the induction period, such as within about 7-15 days or within 7-12 days. Additional ranges are also contemplated. In some embodiments, the T cell expander is administered at least 3 days following the last vaccine administration of the induction period.
  • the T cell expander may, for example, first be administered within about 4-20 weeks following initiation of the vaccination(s) (i.e., following the first vaccination of the induction period), or within about 6-16 weeks following the first vaccination of the induction period, or within about 8-12 weeks following the first vaccination of the induction period, such as, e.g., 11 weeks following the first vaccination of the induction period.
  • administration comprises administration of each of the neoepitope-specific DNA-based cancer vaccine and the T cell expander to align or substantially align the peak T cell responses of both the neoepitope-specific DNA-based cancer vaccine and the T cell expander to thereby achieve an optimized (and preferably synergistic) T cell response.
  • the T cell expander is administered at a period of time following administration of one or more doses of the neoantigen-based DNA cancer vaccine, e.g., following 1-5 doses (i.e., vaccinations), or following 1-4 doses (vaccinations), or following 1-3 doses (vaccinations), or following 1-2 doses (vaccinations) e.g., to thereby result in an enhancement of the specific T cell response.
  • the T cell expander is administered following 2 or 3 vaccinations or 4 vaccinations.
  • the T cell expander is administered following 4 vaccinations.
  • the T cell expander is administered from 1-20 days following the last vaccination of the induction period.
  • the T cell is initially administered on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 days following the last vaccination of the induction period.
  • the vaccination period comprises 4 vaccinations
  • the first dose of the T cell expander is administered from 5-10 days following the 4 th vaccination, e.g., e.g., 5, 6, 7, 8, 9, or 10 days following the 4 th vaccination, e.g., on day 7.
  • the vaccine and the T cell expander are administered on either the same day or on different days.
  • the vaccine and the T cell expander are administered on the same day.
  • the vaccine induction period as described above comprises more than one vaccination, each subsequent vaccination separated by 1 week, 2 weeks, 3 weeks, or 4 weeks or more following the first administration.
  • the vaccination induction period comprises 4 separate vaccinations, each separated by from 1-8 weeks, or from 2-8 weeks, or from 2-6 weeks, or from 3-8 weeks, or from 4-8 weeks, or from 4-6 weeks.
  • the vaccine is administered every 3 weeks for the first one, two or three or four doses, following by a longer interval between vaccinations, e.g., every 4 weeks, or every 5 weeks or every 6 weeks, or longer.
  • the checkpoint inhibitor when comprised in the combination therapy, is administered, for one or for multiple rounds (i) on the same day as the neoantigen-based DNA cancer vaccine is administered, (ii) on the same day as the T cell expander is administered (iii) following administering of the neoantigen- based DNA cancer vaccine, (iv) following administering of the T cell expander, (v) following administering of the neoantigen-based DNA cancer vaccine but before administering of the T cell expander.
  • an exemplary order of administration is neoantigen-based DNA cancer vaccine, T cell expander, followed by checkpoint inhibitor.
  • the checkpoint inhibitor such as an anti-PD-1 antibody or other suitable CPI
  • the checkpoint inhibitor is administered more than once over the course of treatment.
  • the checkpoint inhibitor is initially administered following an initial vaccination and following administration of the T cell expander.
  • the checkpoint inhibitor is initially administered following an initial vaccination but prior to administration of the T cell expander.
  • the check point inhibitor when comprised in the combination therapy, is administered prior to first vaccination (i.e., administration) of the neoantigen-based DNA cancer vaccine and prior to the first administration of the T cell expander.
  • Exemplary checkpoint inhibitors include, e.g., an anti -PD- 1 antibody, an anti-
  • CTLA-4 antibody or an anti-PD-Ll antibody.
  • the cancer comprises a cancerous tumor and the method is effective to reduce the size of the cancerous tumor when compared to the size of the tumor prior to treatment.
  • the cancer comprises a cancerous tumor, and the method is effective to reduce the size of the cancerous tumor by at least about 30% (partial response), or by at least about 40%, or by at least about 50%, or by at least about 60%, or by at least about 70%, or at least about 80%, or at least about 90%, or to result in complete tumor regression, when compared to the size of the tumor prior to the administering.
  • the cancer comprises a cancerous tumor and the method is effective to result in complete tumor regression.
  • FIG. 1 provides the amino acid sequence of the exemplary VB10.NEO pDNA mouse construct, VB4011 (SEQ ID NO: l), encoding 10 neoepitopes from B16, wherein each peptide is separated by a ten amino acid linker (GGGGS)2 (SEQ ID NO:33), as described in Table 2.
  • FIGs. 2A-2D illustrate, as described in Example 1, that administration of a T cell expander such as RSLAIL-2 boosts the neoepitope-specific IFN-g T cell response when administered in combination with an exemplary immunotherapeutic DNA-based neoantigen vaccine, VB10.NEO in a B16 mouse melanoma model.
  • FIG. 2A is a graph of the total T cell responses (number of IFN-y+ spots/10 6 splenocytes) in a B16 tumor model after treatment with a control (VB1026), the vaccine alone (VB4011) or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • FIG. 1 is a graph of the total T cell responses (number of IFN-y+ spots/10 6 splenocytes) in a B16 tumor model after treatment with a control (VB1026), the vaccine alone (VB4011) or the combination of the T cell expander and the vaccine.
  • FIG. 2B is a graph of the total T cell responses per spleen, that is the number of IFN-y+ spots/spleen, after treatment with a control (VB1026), the vaccine alone (VB4011) or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • FIG. 2C is a graph of the total CD8+ T cell responses (splenocytes depleted of CD4+ T cells using anti-CD4 Ab coated Dynabeads) as the number of IFN-y+ spots/spleen after treatment with a control (VB1026), the vaccine alone (VB4011) or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • 2D is a graph of the total CD4+ T cell responses (splenocytes depleted of CD8+ T cells using anti-CD8 Ab coated Dynabeads) as the number of IFN-y+ spots/spleen after treatment with a control (VB1026), the vaccine alone (VB4011) or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • the T cell expander synergizes vaccine induced neoepitope-specific IFN-g T cell responses in a mouse melanoma model.
  • FIGs. 3A-3D illustrate, as described in Example 2, that administration of a T cell expander boosts the neoepitope-specific IFN-g T cell response when administered in combination with an exemplary immunotherapeutic DNA-based neoantigen vaccine, VB10.NEO in a CT26 mouse colon carcinoma model.
  • FIG. 3A is a graph of the total T cell responses (number of IFN-y+ spots/10 6 splenocytes) in a CT26 tumor model after treatment with a control (VB1026), the vaccine alone (VB4061), the T cell expander alone (RSLAIL- 2), or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • FIG. 3A is a graph of the total T cell responses (number of IFN-y+ spots/10 6 splenocytes) in a CT26 tumor model after treatment with a control (VB1026), the vaccine alone (VB4061), the T cell expander alone (RSLAIL- 2), or the combination of
  • 3B is a graph of the total T cell responses per spleen, that is the number of IFN-y+ spots/spleen, after treatment with a control (VB1026), the vaccine alone (VB4061), the T cell expander alone (RSLAIL-2), and the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • 3C is a graph of the total CD8+ T cell responses (splenocytes depleted of CD4+ T cells using anti-CD4 Ab coated Dynabeads) as the number of IFN-y+ spots/spleen after treatment with a control (VB1026), the vaccine alone (VB4061), the T cell expander alone (RSLAIL-2), or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • VB1026 the total CD8+ T cell responses
  • VB4061 the vaccine alone
  • RSLAIL-2 T cell expander alone
  • 3D is a graph of the total CD4+ T cell responses (splenocytes depleted of CD8+ T cells using anti-CD8 Ab coated Dynabeads) as the number of IFN-y+ spots/spleen after treatment with a control (VB1026), the vaccine alone (VB4061), the T cell expander alone (RSLAIL-2), or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2).
  • the T cell expander synergizes vaccine induced neoepitope-specific IFN-g T cell responses in a mouse colon carcinoma model.
  • FIGs. 4A-4D illustrate, as described in Example 3, that administration of a T cell expander boosts the neoepitope-specific IFN-g T cell response when administered in combination with an exemplary immunotherapeutic DNA-based neoantigen vaccine,
  • FIG. 4A is a graph of the tumor growth shown as tumor volume (cm 3 ) for 5-25 days post injection of CT26 tumor cells after administration of the vaccine alone (VB4061), the combination of the vaccine and an anti-PD-1 antibody (VB4061 + anti -PD 1 Ab), or the combination of the vaccine, an anti-PD-1 antibody, and a T cell expander (VB4061 + anti-PDl Ab + RSLAIL-2) in a CT26 mouse colon carcinoma model.
  • FIG. 4A is a graph of the tumor growth shown as tumor volume (cm 3 ) for 5-25 days post injection of CT26 tumor cells after administration of the vaccine alone (VB4061), the combination of the vaccine and an anti-PD-1 antibody (VB4061 + anti -PD 1 Ab), or the combination of the vaccine, an anti-PD-1 antibody, and a T cell expander (VB4061 + anti-PDl Ab + RSLAIL-2) in a CT26 mouse colon carcinoma model.
  • 4B is a graph of the percentage of tumor-free mice (i.e., mice that never established a tumor) for 0-49 days post injection of CT26 tumor cells after administration of the vaccine alone (VB4061), the combination of the vaccine and an anti-PD-1 antibody (VB4061 + anti-PDl Ab), or the combination of the vaccine, an anti- PD-1 antibody, and a T cell expander (VB4061 + anti-PDl Ab + RSLAIL-2).
  • Tuor take refers to mice that never established a tumor, which differs from mice that established a tumor which then later regressed or was cleared.
  • 4C is a graph of the % survival of mice for 0-80 days post injection of CT26 tumor cells after administration of the vaccine alone (VB4061), the combination of the vaccine and an anti-PD-1 antibody (VB4061 + anti- PDl Ab), or the combination of the vaccine, an anti-PD-1 antibody, and a T cell expander (VB4061 + anti-PDl Ab + RSLAIL-2).
  • VB4061 the combination of the vaccine and an anti-PD-1 antibody
  • a T cell expander VB4061 + anti-PDl Ab + RSLAIL-2).
  • 4D is a graph of the percentage of tumor-free mice for 0-70 days post injection of CT26 tumor cells after administration of the vaccine alone (VB4061), the combination of the vaccine and an anti-PD-1 antibody (VB4061 + anti- PDl Ab), or the combination of the vaccine, an anti-PD-1 antibody, and a T cell expander (VB4061 + anti-PDl Ab + RSLAIL-2) after re-challenge with 5xl0 4 CT26 tumor cells without retreatment.
  • VB4061 + anti-PDl Ab + RSLAIL-2 T cell expander
  • FIGs. 5A-5C provide the results of administration of a T cell expander that is postponed after one or more administrations of an anticancer vaccine as described further in Example 1.
  • FIG. 5A is a graph of the total T cell responses (number of IFN-y+ spots/spleen) in a B 16 tumor model after treatment with a control (VB1026), the vaccine alone (VB4011) administered on day 1, or the combination of the T cell expander and the vaccine (VB4011 + RSLAIL-2) administered on day 11 or day 14 after the anticancer vaccine.
  • T cell response was analyzed at days 14, 18 or 21 after anticancer vaccine, and 7 days after dosing the T cell expander.
  • FIG. 5B is a graph of the total T cell responses (number of IFN-y+ spots/spleen) in a CT26 tumor model after treatment with a control (VB1026), the vaccine alone (VB4061) on days 1 and 21 and the combination of the T cell expander and the vaccine (VB4061 + RSLAIL-2) administered on day 21 (same day as 2 nd vaccination) or day 24 (3 days post 2 nd vaccination).
  • ELISpot was performed 7 days following administration of RSLAIL-2 (e.g., 21 + 7 or 24 +
  • the day in the figure refers to when splenocytes were analyzed in ELISpot. (Vaccine is administered day 1).
  • Vaccine is administered day 1.
  • RSLAIL-2 d21 administration of both the vaccine and RSLAIL-2 (second doses) occurred on the same day.
  • VB4061 + RSLAIL-2 d28 RSLAIL-2 was administered three days (day 24) following the second administration of the vaccine (on day 21).
  • FIG. 1 The day in the figure refers to when splenocytes were analyzed in ELISpot.
  • 5C is a graph of the total T cell responses (number of IFN-y+ spots/spleen) in a B16 tumor model after treatment with three administrations of a control (3x VB1026), three administrations of the vaccine alone (3xVAC), three administrations of the vaccine with administration of the T cell expander on the same day as the third vaccine (3xVAC + RSLAIL-2 d35), and three administrations of the vaccine with administration of the T cell expander three days following the third vaccine dose (3x VAC + RSLAIL-2).
  • This figure indicates that when RSLAIL-2 is administered as late as the 3 rd vaccination, the difference between same day and 3-days postponed is no longer present. Postponed administration of the T cell expander appears to synergize the specific T cell response.
  • FIGS. 6A-6C provide graphs of the tumor length (mm), where the T cell expander was administered days 0, 9, 18, 27 (dotted lines) starting when the tumor burden at first administration is 1-5 mm (FIG. 6A), 6-10 mm (FIG. 6B), or >10 mm (FIG. 6C) in a CT26 mouse colon carcinoma model.
  • Mice were treated with the vaccine VB4061 + anti- PD-1 antibody in addition (red, green and blue legend), or VB4061 + anti.PD-1 only (black legend).
  • Pink lines in FIGs. 6A and 6C corresponds to RSLAIL-2 at day 32. A complete response was observed in a greater number of mice where the tumor size was ⁇ 6 mm at the time of the first administration of the T cell expander.
  • FIGs. 7A-7B illustrate that administration of a T cell expander provides rapid, complete and long lasting regression of relatively small tumors and long lasting stabilization of larger tumors when administered in combination with an exemplary immunotherapeutic DNA-based neoantigen vaccine, VB4061, and an anti-PD-1 antibody in a CT26 mouse colon carcinoma model.
  • FIG. 7A is a graph of the tumor growth shown as tumor length (mm) for 0-42 days post injection of CT26 tumor cells as a control.
  • FIG. 7B is a graph of the tumor growth shown as tumor length (mm) for 0-56 days post injection of CT26 tumor cells after administration of a combination of the vaccine (VB4061), an anti-PD-1 antibody, and a T cell expander in a CT26 mouse colon carcinoma model.
  • FIG. 8 provides the amino acid sequence of the VB10.NEO pDNA mouse construct, VB4061 (SEQ ID NO:2), encoding 20 neoepitopes from CT26, wherein each peptide is separated by a ten amino acid glycine/serine rich linker (GGGGS)2, as described in Table 2.
  • FIG. 9 provides the amino acid sequences of the individual neoepitopes from
  • CT26 (SEQ ID NOs:3-22) included in the VB4061 mouse construct.
  • FIG. 10 provides the amino acid sequences of the individual neoepitopes from
  • FIGs. 11A-D provide an outline of dosing and assessments performed throughout the clinical study described in Example 4.
  • FIG. 12 provides a complete pVBlO.NEO plasmid backbone sequence including coding sequences of the targeting module (hMIP-la, nucleotides 1143-1421) and the dimerization module (hi and h4 and CH3 domains of hIgG3, nucleotides 1422-1853) of the expression product (SEQ ID NO:77).
  • the grey blocks are the internal Sfll cloning sites (nucleotides 1854-1866 and 1869-1881). Italic sequences are the flanking Notl/Bglll restriction sites (nucleotides 1884-1889).
  • Underlined sequences are glycine/serine-rich linkers (nucleotides 1503-1532 and 1854-1868). The nucleotide numbering does not include the neoantigenic module nucleotides).
  • FIG. 13 provides a pVBlO.NEO plasmid map.
  • the instant disclosure relates to (among other things) the field of
  • T cell expander a T cell expanding compound
  • a personalized neoantigen DNA cancer vaccine in combination with a T cell expanding compound (“T cell expander”), i.e., a compound capable of driving specific clonal T cell expansion to vaccine epitopes, optionally further combined with a checkpoint inhibitor.
  • T cell expander i.e., a compound capable of driving specific clonal T cell expansion to vaccine epitopes, optionally further combined with a checkpoint inhibitor.
  • references to a range or sub-range is meant to expressly recite sub-ranges formed by any two members of a disclosed range.
  • a range described as being from 20 to 50, or from 10 to 30, will thereby expressly include ranges from 10 to 20, 20 to 30, 10 to 50, 30 to 50, and so forth.
  • substantially or “essentially” means nearly totally or completely, for instance, about 95% or greater of a given quantity.
  • PEG polyethylene glycol
  • a "PEG polymer” or a polyethylene glycol is one in which substantially all (preferably all) monomeric subunits are ethylene oxide subunits, though, the polymer may contain distinct end capping moieties or functional groups, e.g., for conjugation.
  • PEG polymers for use in the moieties described herein will typically comprise one of the two following structures: "-(CEhCEhOV or "-(CH2CH 2 0)n-iCH 2 CH2-,” depending upon whether or not the terminal oxygen(s) has been displaced, e.g., during a synthetic transformation.
  • variable (n) will typically fall within a range from about 3 to 4000, and the terminal groups and architecture of the overall PEG can vary.
  • Preferred ranges /values for (n) for the T cell expander, RSLAIL-2 (described in greater detail below), e.g., in reference to Formulas (I), (II), (III) and (IV), include from about 200 to 300, and about 227.
  • Additional exemplary ranges for (n) are those suitable to provide a branched polymer such as provided in Formulas (I), (II), (III) and (IV), having an overall weight average molecular weight in a range of from about 250 daltons to about 90,000 daltons.
  • Additional exemplary ranges for (n) are those suitable to provide a branched polymer such as provided in Formulas (I), (II), (III) and (IV), having an overall weight average molecular weight in a range selected from about 1,000 daltons to about 60,000 daltons, in a range of from about 5,000 daltons to about 60,000 daltons, in a range of about 10,000 daltons to about 55,000 daltons, in a range of from about 15,000 daltons to about 50,000 daltons, and in a range of from about 20,000 daltons to about 50,000 daltons.
  • Branched in reference to the geometry or overall structure of a polymer, optionally forming part of a polymer-conjugate, refers to a polymer having two or more polymer "arms” or“chains” extending from a branch point or central structural feature.
  • a branched polymer comprises two polymer arms or chains emanating from a central structural feature.
  • a covalent“releasable” linkage for example, in the context of a polyethylene glycol that is covalently attached to an active moiety such as an interleukin-2 (e.g., aldesleukin), is one that releases under physiological conditions by any suitable release mechanism to thereby release or detach the polyethylene glycol polymer from the active moiety.
  • an interleukin-2 e.g., aldesleukin
  • Molecular weight in the context of a water-soluble polymer can be expressed as either a number average molecular weight or a weight average molecular weight. Unless otherwise indicated, all references to molecular weight herein refer to the weight average molecular weight. Both molecular weight determinations, number average and weight average, can be measured using gel permeation chromatography or other liquid chromatography techniques.
  • PEG polymers are typically polydisperse (i.e., number average molecular weight and weight average molecular weight of the polymers are not equal), possessing low polydispersity values of preferably less than about 1.2, more preferably less than about 1.15, still more preferably less than about 1.10, yet still more preferably less than about 1.05, and most preferably less than about 1.03.
  • protein protein
  • polypeptide peptide
  • peptide refers to any peptide-linked chain of amino acids, regardless of length, co- translational or post-translational modification.
  • “Pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” refers to a component that may be included in the compositions described herein and causes no significant adverse toxicological effects to a subject.
  • patient refers to a living organism suffering from or prone to a condition that can be prevented or treated by administration of a compound or composition or combination as provided herein, such as a cancer, and includes both humans and animals.
  • Subjects include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and preferably are human.
  • administering refers to the delivery of a therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in the art.
  • Exemplary routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion.
  • parenteral administration as used herein means modes of
  • administration other than enteral and topical administration usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal,
  • a therapeutic agent can be administered via a non-parenteral route, or orally.
  • Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically.
  • Administering of one or more therapeutic agents can also be performed for each of the therapeutic agents, for example, once, a plurality of times, and/or over one or more extended periods.
  • a “cancer” refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body.
  • a “cancer” or “cancer tissue” includes a tumor, and as used herein, encompasses both a solid tumor as well as tumor cells found in a bodily fluid such as blood, and includes metastatic cancer. Unregulated cell division and growth results in the formation of malignant tumors that can invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or
  • the distal tumors can be said to be "derived from” a pre metastasis tumor.
  • immunotherapy refers to the treatment of a subject by a method comprising inducing, enhancing, suppressing, or otherwise modifying an immune response.
  • tumor specific antigen comprising one or more mutations as compared to the host’s exome and is used
  • tumor antigen any immunogenic mutation in a tumor antigen and is used synonymously herein with the term,“cancer neoepitope”.
  • A“tumor neoepitope sequence” as used herein is the sequence comprising the neoepitope in an antigenic subunit, and is used synonymously with the term,“cancer neoepitope sequence”.
  • a“plurality” refers to 3 or more of a given item.
  • therapeutic anticancer vaccine and“therapeutic cancer vaccine” are used synonymously to describe a vaccine that is used for destroying or reducing the number of tumor cells already present in a patient.
  • a "therapeutically effective amount” or “therapeutically effective dosage” of a therapeutic agent is any amount of an agent, when used alone or in combination with another therapeutic agent, that is effective to, for example, protect a subject against the onset of a disease such as cancer or promote disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
  • the ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays. See, for instance, the supporting examples.
  • substantially homologous or“substantially identical” means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences.
  • a sequence having greater than 95 percent homology (identity), equivalent biological activity (although not necessarily equivalent strength of biological activity), and equivalent expression characteristics to a given sequence is considered to be substantially homologous (identical).
  • truncation of the mature sequence should be disregarded.
  • the phrase "at least 80% sequence identity" may be used herein. This expression refers to a sequence identity of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to the respective reference polypeptide or to the respective reference
  • polypeptide in question and the reference polypeptide exhibit the indicated sequence identity over a continuous stretch of 20, 30, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids or over the entire length of the reference polypeptide.
  • polynucleotide in question and the reference polynucleotide exhibit the indicated sequence identity over a continuous stretch of 60, 90, 120, 135, 150, 180, 210, 240, 270, 300 or more nucleotides or over the entire length of the reference polypeptide.
  • a combination immunotherapy method based upon administration of a personalized neoantigen-based DNA cancer vaccine and a T cell expander, i.e., an entity that is effective to drive specific clonal T cell expansion to the vaccine epitopes.
  • IL-2 stimulates immune cell proliferation and activation through a receptor signaling complex containing alpha (IL2Ra, CD25), beta (IL2R , CD122) and common gamma chain receptors (y C’ CD 132).
  • IL-2 binds to heterodimeric IL2R.Py receptor leading to desired expansion of tumor killing CD8+ memory effector T (CD8 T) cells.
  • CD8 T memory effector T
  • IL-2 also binds to its heterotrimeric receptor IL2Ro y with greater affinity, which expands immunosuppressive CD4+, CD25+ regulatory T cells (Tregs), which may lead to an undesirable effect for cancer immunotherapy.
  • a treatment modality that combines a neoantigen-based DNA cancer vaccine against tumor specific antigens with administration of a T cell expander.
  • the T cell expander is an IL-2Raf -biased agonist.
  • the treatment methods provided herein comprise administering (i) a vaccine, i.e., an anti cancer DNA vaccine directed to a plurality of neoepitopes from tumor neoantigens (“neoantigen-based DNA cancer vaccine”), and (ii) a compound effective to stimulate/expand production of T cells (i.e., effector T cells,“a T cell expander”) for treating a patient having cancer, optionally in combination with a check point inhibitor.
  • a vaccine i.e., an anti cancer DNA vaccine directed to a plurality of neoepitopes from tumor neoantigens (“neoantigen-based DNA cancer vaccine”)
  • a compound effective to stimulate/expand production of T cells i.e., effector T cells,“a T cell expander”
  • compositions, combinations, and methods provided herein find use in, among other things, both clinical and pre-clinical applications.
  • administration of a T cell expander, such as RSLAIL-2 in combination with a neoantigen- based DNA cancer vaccine, optionally further combined with a checkpoint inhibitor, is effective to significantly expand/enhance the T cell response to vaccine-encoded neoantigens in a subject, to thereby provide a strong-neoantigen focused immune response for fighting cancer.
  • VB10.NEO alone. Mice treated with VB10.NEO in combination with the T cell expander, RSLAIL-2, showed both a stronger response to each neoepitope and to increased numbers of neoepitopes, demonstrating that both the breadth and depth of the immune response were elevated as a result of the combination therapy.
  • the VB10.NEO and RSLAIL-2 combination produced an even greater effect on CD8+ T cell responses as the combination elicited a neoepitope-specific CD8+ T cell response to more neoepitopes compared to either immunotherapeutic agent when administrated alone, further strengthening the combination’s ability to induce strong neoepitope-specific CD8+ T cell responses.
  • mice treated with the exemplary triple immunotherapeutic combination of VB10.NEO, RSLAIL-2 and an anti-PD- 1 antibody (as representative of a combination therapy comprising administration of a personalized neoantigen-based DNA cancer vaccine, a T cell expander, and optionally, a checkpoint inhibitor), further demonstrating the advantages of combining such reagents to thereby activate non-overlapping mechanisms of immunotherapy and create an effective treatment of established tumors.
  • therapeutic anticancer neoepitope vaccines suitable for use in the methods provided herein are described in U.S. Patent Publication No. 2019/0022202, along with methods describing their preparation and use, which is incorporated herein by reference.
  • the therapeutic neoepitope vaccine is an anticancer DNA vaccine directed to a plurality of neoepitopes from tumor neoantigens.
  • the neoepitopes comprised in the individualized DNA vaccine are presented to the immune system as a dimeric protein called a vaccibody.
  • Dimeric proteins called vaccibodies are described in detail in WO 2004/076489, which is incorporated herein by reference.
  • the neoantigen-based DNA cancer vaccine may comprise an immunologically effective amount of a DNA polynucleotide comprising a nucleotide sequence encoding at least (i) a targeting unit (also referred to as a targeting module), (ii) a dimerization unit (also referred to as a dimerization module), (iii) a first linker and (iv) an antigenic unit (also referred to as an antigenic module), wherein the antigenic unit comprises n-1 antigenic subunits; n is an integer of from 3 to 50.
  • Each antigenic subunit comprises at least a part of a cancer neoepitope sequence and a second linker. Additionally, the antigenic unit further comprises a final cancer neoepitope sequence.
  • the vaccines suitable for use in the instant methods are designed to evoke a cell-mediated immune response through activation of T cells against the neoantigens.
  • T cells recognize neoepitopes when they have been processed and presented complexed to a MHC molecule.
  • the neoantigen vaccine comprises a DNA polynucleotide encoding a polypeptide comprising three units, i.e. a targeting unit (or module), a dimerization unit (or module) and an antigenic unit (or module). Due to the dimerization unit, the polypeptide forms a dimeric protein called a vaccibody.
  • the genes encoding the three units are genetically engineered to be expressed as one gene.
  • the poly peptides/ dimeric proteins target antigen presenting cells (APCs), which results in enhanced vaccine potency compared to identical non-targeted antigens. See, for example, FIG. 13 which provides an exemplary plasmid map illustrating different functional elements.
  • the antigenic unit comprises antigenic subunits, wherein each subunit comprises a cancer neoepitope sequence or at least a part of a cancer neoepitope sequence.
  • the neoepitope sequence is obtained by sequencing tumor DNA (or RNA) and identifying tumor specific mutations representing neoantigens.
  • a personalized neoantigen vaccine is obtained that specifically targets the identified tumor antigens.
  • the therapeutic anticancer neoepitope vaccine comprises an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding (i) a targeting unit, (ii) a dimerization unit, (iii) a first linker, (iv) an antigenic unit, wherein the antigenic unit comprises n-1 antigenic subunits, and each subunit comprises at least a part of a cancer neoepitope sequence and a second linker, where the antigenic unit further comprises a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50.
  • the vaccine comprises n neoepitopes or neoepitope sequences and n-1 second linkers, wherein n is an integer from 3 to 50 (with additional exemplary sub-ranges provided below).
  • the antigenic unit comprises a plurality of tumor neoepitopes, wherein each neoepitope corresponds to a mutation identified in a tumor neoantigen in a specific patient. That is to say, all selected neoantigens are unique and specific for the individual patient.
  • the mutation may be any mutation leading to a change in at least one amino acid.
  • the mutation may be one of the following: a non-synonymous mutation leading to a change in the amino acid, a mutation leading to a frame shift and thereby a completely different open reading frame in the direction after the mutation, a read-through mutation in which a stop codon is modified or deleted leading to a longer protein with a tumor-specific neoepitope, splice mutations that lead to a unique tumor-specific protein sequence, chromosomal rearrangements that give rise to a chimeric protein with a tumor-specific neoepitope at the junction of the two proteins.
  • each subunit consists of a tumor neoepitope sequence and a second linker, whereas the last subunit comprises a neoepitope only, i.e. no second linker.
  • each neoepitope is presented in an optimal way to the immune system.
  • the cancer neoepitope sequence preferably has a length suitable for presentation by the MHC molecules.
  • the cancer neoepitope is from 7 to 30 amino acids long. More preferred are cancer neoepitope sequences having a length of from 7 to 10 amino acids or cancer neoepitope sequences having a length of from 13 to 30 amino acids, e.g., from 20 to 30 amino acids, e.g., comprised of 27 amino acids.
  • a plurality of different neoepitopes are included in the antigenic unit.
  • a preferred approach is to include as many neoepitopes as possible into the vaccine to thereby attack the tumor efficiently whilst not compromising the vaccine’s ability to activate T cells against the neoepitopes due to dilution of the desired T cell effect. Also, to secure that all neoepitopes are loaded efficiently to the same antigen presenting cell, the neoepitopes are arranged as one amino acid chain instead of as discrete peptides.
  • the tumor exome is analyzed to identify neoantigens and select the most antigenic neoepitopes.
  • at least 3 neoepitopes are incorporated into the vaccine, preferably at least 5 neoepitopes, more preferably at least 7 neoepitopes, such as at least 10 neoepitopes, etc., in order to efficiently be able to target substantially all tumor cells.
  • the vaccine comprises at least 10 neoepitopes.
  • the vaccine comprises at least 15 neoepitopes, such as at least 20 neoepitopes.
  • the vaccine may comprise from 3 to 50 neoepitopes, or from 3 to 30 neoepitopes, or from 3 to 20 neoepitopes, or from 3 to 15 neoepitopes, such as from 3 to 10 neoepitopes, and consequently n is preferably an integer of from 3 to 50, such as from 3 to 30, such as from 5 to 25, such as from 3 to 20, such as from 3 to 15, such as from 3 to 10.
  • the vaccine comprises from 10 to 20 neoepitopes.
  • the antigenic unit may, for example, comprise one copy of each cancer neoepitope, so that when 10 neoepitopes are included in the vaccine, a cell-mediated immune response against 10 different neoepitopes can be elicited.
  • the antigenic unit may comprise at least two copies of at least one neoepitope in order to strengthen the immune response to these neoepitopes.
  • the length of the antigenic unit is primarily determined by the length of the neoepitopes and the number of neoepitopes arranged in the antigenic unit, and is from, for example, about 21 to 1500, preferably from about 30 amino acids to about a 1000 amino acids, more preferably from about 50 to about 500 amino acids, such as from about 100 to about 400 amino acids, from about 100 to about 300 amino acids.
  • the neoepitopes may be ordered in the antigenic unit as described below, in order to enhance the immune response.
  • the antigenic subunits may be arranged in the order of more antigenic to less antigenic in the direction from the first linker towards the final neoepitope.
  • the hydrophilicity/hydrophobicity varies greatly among the neoepitopes, it is preferred that the most hydrophobic antigenic subunit(s) is/are substantially positioned in the middle of the antigenic unit and the most hydrophilic antigenic subunit(s) is/are positioned at the beginning and/or end of the antigenic unit.
  • the neoepitopes may be arranged alternating between a hydrophilic and a hydrophobic neoepitope.
  • the GC rich neoepitopes are spaced so that GC clusters are avoided, preferably GC rich neoepitopes are spaced by at least one subunit.
  • the second linker is designed to be non-immunogenic and is preferably also a flexible linker, whereby the tumor neoepitopes, in spite of the high numbers of antigenic subunits present in the antigenic unit, are presented in an optimal manner to the T cells.
  • the length of the second linker is from 4 to 20 amino acids to secure the flexibility.
  • the length of the second linker is from 8 to 20 amino acids, such as from 8 to 15 amino acids, for example 8 to 12 amino acids or such as for example from 10 to 15 amino acids.
  • the length of the second linker is 10 amino acids.
  • the vaccine encodes a protein comprised of a neoepitope antigenic unit comprising 10 neoepitopes, wherein the second linkers have a length of from 8 to 20 amino acids, such as from 8 to 15 amino acids, for example 8 to 12 amino acids or such as, for example, from 10 to 15 amino acids.
  • the vaccine encodes a protein comprised of a neoepitope antigenic unit comprising 10 neoepitopes, where the second linkers have a length of 10 amino acids.
  • the DNA vaccine encodes a protein comprised of a neoepitope antigenic unit comprising from 10-20 neoepitopes, each of 27 amino acids, where the second linkers have a length of 10 amino acids.
  • the second linker is preferably identical in all antigenic subunits. If, however, one or more of the neoepitopes comprise an amino acid motif similar to the linker, it may be an advantage to substitute the neighboring second linkers with a second linker of a different sequence. Also, if a neoepitope-second linker junction is predicted to constitute an epitope in itself, then a second linker of a different sequence might be used.
  • the second linker is preferably a serine-glycine rich linker, such as a flexible GGGGS (SEQ ID NO:34) linker, such as, for example, GGGSS (SEQ ID NO:35), GGGSG (SEQ ID NO:36), GGGGS (SEQ ID NO:34) or multiple variants thereof such as GGGGSGGGGS (SEQ ID NO:33) or (GGGGS)m, (GGGSS)m, (GGGSG)m.
  • m is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5), from 1 to 4 or from 1 to 3. In some preferred embodiments, m is 2.
  • the serine-glycine linker further comprises at least one leucine (L), such as at least 2 or at least 3 leucines.
  • L leucine
  • the serine-glycine linker may for example comprise 1, 2, 3 or 4 leucines. In some instances, the serine-glycine linker comprises 1 leucine or 2 leucines.
  • second linkers include the following: for example, the second linker may comprise or consist of the sequence LGGGS (SEQ ID NO:37), GLGGS (SEQ ID NO:38), GGLGS (SEQ ID NO:39), GGGLS (SEQ ID NO:40) or GGGGL (SEQ ID NO:41); alternatively, the second linker may comprise or consist of a sequence LGGSG (SEQ ID NO:42), GLGSG (SEQ ID NO:43), GGLSG (SEQ ID NO:44), GGGLG (SEQ ID NO:45) or GGGSL (SEQ ID NO:46); or the second linker may comprise or consist of the sequence LGGSS (SEQ ID NO:47), GLGSS (SEQ ID NO:48), GGLSS (SEQ ID NO:49), GGGLS (SEQ ID NO:50) or GGGSL (SEQ ID NO:51).
  • the second linker may comprises or consist of the sequence LGLGS (SEQ ID NO:52), GLGLS (SEQ ID NO:53), GLLGS (SEQ ID NO:54), LGGLS (SEQ ID NO:55) or GLGGL (SEQ ID NO:56), or may comprise or consist of the sequence LGLSG (SEQ ID NO:57), GLLSG (SEQ ID NO:58), GGLSL (SEQ ID NO:59), GGLLG (SEQ ID NO:60) or GLGSL (SEQ ID NO:61), or may comprise or consist of the sequence LGLSS (SEQ ID NO:62), GLGLS (SEQ ID NO:63), GGLLS (SEQ ID NO:64), or GLGSL (SEQ ID NO:65).
  • Additional exemplary second linkers for use in the neoepitope antigenic unit separating the neoepitopes include serine-glycine rich linkers such as the following:
  • the second linker is selected from linkers of SEQ ID NO:67 to SEQ ID NO:76.
  • the second linker is selected from linkers of SEQ ID NO:67 to SEQ ID NO:76, in order of preference with a linker of SEQ ID NO:67 being more preferred than a linker of SEQ ID NO: 68, and so forth.
  • the linkers may change from construct to construct for the various individualized vaccines, because in assembling the neoepitope antigenic unit for the construct, the junctional sequences are evaluated.
  • a first preferred linker may be replaced with another candidate linker that excludes a junctional epitope that resembles a sequence found in the human proteome.
  • Preferred serine/gly cine-rich linkers e.g., 10 amino acid linkers, contain from 6 to 9 glycines (e.g., 6, 7, 8 or 9), or from 6 to 8 glycines. In some preferred embodiments, the remaining non-glycine amino acids contained in the linker are serine(s).
  • Examples of preferred vaccines include those comprising at least 10 neoepitopes that are separated by 10 amino acid linkers, or those comprising at least 15 neoepitopes that are separated by 10 amino acid linkers, such as at least 20 neoepitopes that are separated by 10 amino acid linkers.
  • targeting unit refers to a unit that delivers the polypeptide/protein with its antigen to an antigen presenting cell for MHC class Il-restricted presentation to CD4+ T cells or for providing cross presentation to CD8+ T cells by MHC class I restriction.
  • the targeting unit is connected through the dimerization unit to the antigenic unit, wherein the latter is in either the COOH-terminal or the ML-terminal end of the poly peptide/ dimeric protein. It is preferred that the antigenic unit is in the COOH- terminal end of the polypeptide/dimeric protein.
  • the targeting unit is designed to target the polypeptide/dimeric protein to surface molecules expressed on the relevant antigen presenting cells, such as molecules expressed exclusively on subsets of dendritic cells (DC).
  • DC dendritic cells
  • HLA human leukocyte antigen
  • CD 14 cluster of differentiation 14
  • CD40 cluster of differentiation 40
  • TLRs Toll-like receptors
  • HLA is a major histocompatibility complex (MHC) in humans.
  • the Toll-like receptors may for example include TLR-2, TLR-4 and/or TLR-5.
  • the polypeptide/dimeric protein can be targeted to such surface molecules by means of targeting units comprising for example antibody binding regions with specificity for CD14, CD40, or Toll- like receptor; ligands, e.g. soluble CD40 ligand; natural ligands like chemokines, e.g. RANTES or MIP-la; or bacterial antigens like for example flagellin.
  • An illustrative targeting unit has affinity for an MHC class II protein.
  • the nucleotide sequence encoding the targeting unit encodes the antibody variable domains (VL and VH) with specificity for MHC class II proteins, selected from the group consisting of anti-HLA-DP, anti-HLA-DR and anti-HLA-II.
  • the targeting unit has affinity for a surface molecule selected from the group consisting of CD40, TLR-2, TLR-4 and TLR-5.
  • the nucleotide sequence encoding the targeting unit encodes the antibody variable domains (VL and VH) with specificity for anti- CD40, anti-TLR-2, anti-TLR-4 and anti-TLR-5.
  • the nucleotide sequence encoding the targeting unit encodes flagellin, which has affinity for TLR-5.
  • the targeting unit has affinity for a chemokine receptor selected from CCR1, CCR3 and CCR5.
  • the nucleotide sequence encoding the targeting unit encodes the human chemokine macrophage inflammatory protein- 1 alpha, hMIP-la (LD78beta), which binds to its cognate receptors, CCR1, CCR3 and CCR5 expressed on the cell surface of antigen- presenting cells (APCs). See, e.g., FIG. 12, which includes the nucleotide sequence encoding the VBIO.NEO protein with the targeting unit identified therein (see, e.g., nucleotides 1143- 1421).
  • the term“dimerization unit” as used herein, refers to a sequence of amino acids between the antigenic unit and the targeting unit.
  • the dimerization unit serves to connect the antigenic unit and the targeting unit and facilitates dimerization of two monomeric polypeptides into a dimeric protein.
  • the dimerization unit also provides the flexibility in the polypeptide/dimeric protein to allow optimal binding of the targeting unit to the surface molecules on the antigen presenting cells (APCs), even if they are located at variable distances.
  • the dimerization unit may be any unit that fulfils these requirements.
  • the term "hinge region” refers to a peptide sequence of the dimeric protein that facilitates the dimerization.
  • the hinge region functions as a flexible spacer between the units allowing the two targeting units to bind simultaneously to two target molecules on APCs, even if they are expressed with variable distances.
  • the hinge region may be Ig derived, such as derived from IgG3.
  • the hinge region may contribute to the dimerization through the formation of covalent bond(s), e.g. disulfide bridge(s).
  • the hinge region has the ability to form one or more covalent bonds.
  • the covalent bond can for example be a disulfide bridge.
  • the dimerization unit consists of hinge exons hi and h4 connected through a third linker to a CH3 domain of human IgG3. See, for example, FIG. 12, and the illustrative dimerization unit identified therein (hi and h4 and CH3 domains of hIgG3, nucleotides 1422-1853).
  • the dimerization unit may have any orientation with respect to antigenic unit and targeting unit.
  • the antigenic unit is in the COOH- terminal end of the dimerization unit with the targeting unit in the N-terminal end of the dimerization unit.
  • the antigenic unit is in the N-terminal end of the dimerization unit with the targeting unit in the COOH-terminal end of the dimerization unit. It is preferred that the antigenic unit is in the COOH end of the dimerization unit.
  • the antigenic unit and the dimerization unit are preferably connected through a first linker.
  • the first linker may comprise a restriction site in order to facilitate the construction of the polynucleotide. It is, in some instances, preferred that the first linker is a GLGGL (SEQ ID NO:56) linker or a GLSGL (SEQ ID NO:66) linker.
  • the polynucleotide may further comprise a nucleotide sequence encoding a signal peptide.
  • the signal peptide is constructed to allow secretion of the polypeptide encoded by the polynucleotide in the cells transfected with said polynucleotide. Any suitable signal peptide may be used. Examples of suitable peptides are an Ig VH signal peptide, a human TPA signal peptide, and a signal peptide.
  • the polynucleotide typically comprises a DNA nucleotide sequence, either double stranded or single stranded.
  • the polynucleotide is optimized to the desired species to express a polypeptide, i.e. it is preferred that the polynucleotide sequence is human codon optimized.
  • Exemplary mouse neoantigen-based DNA cancer vaccines comprising VB10.NEO pDNA constructs, VB4011 and VB4061, are described in the supporting examples. Additionally, an exemplary human neoantigen-based DNA cancer vaccine is described in Example 4. An illustrative pVBlO.NEO plasmid map is shown in FIG. 13.
  • the vaccine may further comprise a pharmaceutically acceptable carrier, diluent, adjuvant or buffer.
  • Pharmaceutically acceptable carriers, diluents, and buffers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof.
  • a carrier may include molecules that ease transfection of cells and adjuvants and may include plasmids comprising nucleotide sequences encoding chemokines or cytokines in order to enhance the immune response.
  • the vaccine may be formulated into any suitable formulation, such as a liquid formulation for intradermal or intramuscular injection.
  • the vaccine may be administered in any suitable way for either a polypeptide/protein vaccine or a polynucleotide vaccine, such as administered by injection intradermally, intramuscular, subcutaneously, or by mucosal or epithelial application, such as intranasally, orally, enteral or to the bladder.
  • the vaccine is preferably administered intramuscular or intradermally when the vaccine is a polynucleotide vaccine.
  • the vaccine is administered by intranodal injection.
  • the term“intranodal injection” means that the vaccine is injected into the lymph nodes.
  • a T cell expander is a compound or composition effective to stimulate/expand production of T cells.
  • the T cell expander when administered in combination with the neoantigen-based DNA cancer vaccine, is effective to enhance specific clonal T cell expansion to vaccine epitopes.
  • the T cell expander is effective to enhance specific clonal T cell expansion to vaccine epitopes over that achieved upon administration of the neoantigen-based DNA cancer vaccine in the absence of the T cell expander to a degree that is greater than additive, and the combination is not limited in this regard.
  • the T cell expander is effective to enhance specific clonal T cell expansion to vaccine epitopes in a synergistic fashion over that achieved upon administration of the neoantigen-based DNA cancer vaccine in the absence of the T cell expander.
  • Illustrative T cell expanders include interleukin-2 (e.g., aldesleukin), interleukin-15, and interferon-a, and an anti-CD3 antibody such as, e.g., OKT3.
  • the T cell expander is a prodrug of an interleukin-2 (e.g., aldesleukin, chemical name, des-alanyl-1, serine- 125 human interleukin-2), wherein the interleukin-2 is modified by releasable covalent attachment of multiple polyethylene glycol moieties.
  • the prodrug is essentially inactive upon administration, and following administration, the polyethylene glycol moieties are slowly released to provide bioactive species, thereby avoiding overstimulation of the immune system.
  • Conjugates of an interleukin-2 moiety modified by covalent attachment of one or more polyethylene glycol moieties are described, for example, in U.S. Patent No. 9,861,705.
  • the T cell expander is an interleukin-2 receptor beta (IL-2R ) selective agonist as described, for example, in U.S. Patent No. 10,101,587, and generally referred to therein as RSLAIL-2.
  • IL-2R interleukin-2 receptor beta
  • the releasable PEG comprised in RSLAIL-2 is based upon a 2,7,9-substituted fluorene as shown below, with poly (ethylene glycol) chains extending from the 2- and 7- positions on the fluorene ring via amide linkages (fluorene-C(O)-NH-), and having releasable covalent attachments to interleukin-2 via attachment to a carbamate nitrogen atom attached via a methylene group (-CH2-) to the 9-position of the fluorene ring.
  • the T cell expander is a composition comprising compounds encompassed by the following formula:
  • IL-2 is an interleukin-2; or pharmaceutically acceptable salts thereof, where each“n” is an integer from about 3 to about 4000, or more preferably is an integer from about 200- 300.
  • RSLAIL-2 or multi(2,7-(bis- methoxyPEG-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)interleukin-2.
  • RSLAIL-2 is a composition comprising compounds encompassed by formula (I), that is, having four, five or six branched PEG moieties as shown above, i.e., 2,7-(bis-methoxyPEG-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate moieties, releasably covalently attached to amino groups of IL-2.
  • “n” in each of the polyethylene glycol chains has a value, on average, of about 227 (i.e., where each polyethylene glycol chain extending from the central fluorenyl core has a weight average molecular weight of about 10,000 daltons, such that the weight average molecular weight of the overall branched PEG moiety is about 20,000 daltons), i.e., referred to herein more particularly as multi(2,7-(bis-methoxyPEGiokD-carboxyamide)(9H-fluorene-9- yl)methyl N-carbamate)interleukin-2 or as (2,7-(bis-methoxyPEGiokD-carboxyamide)(9H- fluorene-9-yl)methyl N-carbamate)4-6interleukin-2.
  • the value of“n” in each of the polyethylene glycol chains is substantially the same, that is to say that, for example, the two PEG chains extending from the central fluorenyl core
  • multi(2,7-(bis-methoxyPEG- carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)interleukin-2 comprises compounds encompassed by the following formula:
  • multi(2,7-(bis-methoxyPEG- carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)interleukin-2 comprises compounds encompassed by the following formula:
  • Formula (III) wherein the average number of branched PEG moieties having a structure as shown and releasably covalently attached to the IL-2 moiety is six, i.e., (2,7-(bis-methoxyPEGiokd- carboxyamide)(9h-fluorene-9-yl)methyl N-carbamate)6 avg interleukin-2, also referred to in some instances as falling within the designation“RSLAIL-2” (releasable IL-2).
  • T cell expander compounds and compositions encompassed by Formulae (I), (II), and (III) are generally designated“RSLAIL-2”.
  • the releasable PEG moiety(moieties) comprised in RSLAIL-2 is based upon a 2,7,9-substituted fluorene with poly(ethylene glycol) chains extending from the 2- and 7- positions of the fluorene ring via amide linkages (fluorene-C(O)-NH-), to provide a branched PEG.
  • the fluorenyl-based branched PEG moieties are releasably covalently attached to amino groups of the interleukin-2 moiety.
  • the linkage between interleukin-2 amino groups and the fluorenyl-based branched PEG moiety is a carbamate linkage attached via a methylene group (-CH2-) to the 9-position of the fluorene ring.
  • Releasable PEGs having this general structure typically undergo a b-elimination reaction under physiological conditions to slowly release the PEG moieties that are covalently attached to IL-2. It is believed that the PEG moieties release sequentially following administration.
  • the IL-2R -biased agonist composition contains no more than 10% (based on a molar amount), and preferably no more than 5% (based on a molar amount), of compounds encompassed by the following formula:
  • IL-2 is an interleukin-2 (e.g., aldesleukin), and“m” (referring to the number of branched polyethylene glycol moieties attached to IL-2) is an integer selected from the group consisting of 1, 2, 3, 7 and >7; or pharmaceutically acceptable salts thereof.
  • interleukin-2 e.g., aldesleukin
  • m referring to the number of branched polyethylene glycol moieties attached to IL-2
  • m is an integer selected from the group consisting of 1, 2, 3, 7 and >7; or pharmaceutically acceptable salts thereof.
  • the IL- 2R -biased agonist possesses on average about six branched polyethylene glycol moieties releasably attached to IL-2. See, for example, Formula (III).
  • the IL-2R - selective agonist is generally considered to be an inactive prodrug, i.e., that is inactive upon administration, and by virtue of slow release of the polyethylene glycol moieties in vivo following administration, provides active conjugated forms of interleukin-2 having fewer PEG moieties attached than in the conjugate that is initially administered.
  • references to“multi(2,7-(bis-methoxyPEG- carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)interleukin-2” or“RSLAIL-2” is expressly intended to encompass compounds and compositions as set forth in Formula (I), Formula (II), and/or Formula (III), including compositions encompassed by Formula (IV) in reference to any one or more of Formulae (I), (II) and (III).
  • RSLAIL-2 is considered to be an IL-2R -biased (i.e., selective) agonist.
  • RSLAIL-2 referenced in the accompanying examples exhibits about a 60-fold decrease in affinity to IL-2Ra.p relative to IL-2, but only about a 5- fold decrease in affinity IL-2R relative to IL-2. See, for example, Example 20 in PCT Publication No. WO 2018/132496 describing the binding affinity of RSLAIL-2 to IL-2Ra and IL-2R .
  • the protein is quantified by a method such as a bicinchoninic acid (BCA) assay or by UV analysis, to determine moles of protein in the sample.
  • BCA bicinchoninic acid
  • the PEG moieties are then released by exposing the sample to conditions in which the PEG moieties are released, and the released PEG is then quantified (e.g., by BCA or UV) and correlated with moles protein to determine average degree of PEGylation.
  • RSLAIL-2 can be considered to be an inactive prodrug, i.e., it is inactive upon administration, and by virtue of slow release of the polyethylene glycol moieties in vivo, provides active conjugated forms of interleukin-2 that are effective to achieve sustained concentrations at a tumor site.
  • Additional exemplary compositions of RSLAIL-2 comprise compounds in accordance with the above formulae wherein the overall polymer portion of the molecule has a weight average molecular weight in a range of from about 250 daltons to about 90,000 daltons. Additional suitable ranges include weight average molecular weights in a range selected from about 1,000 daltons to about 60,000 daltons, in a range of from about 5,000 daltons to about 60,000 daltons, in a range of about 10,000 daltons to about 55,000 daltons, in a range of from about 15,000 daltons to about 50,000 daltons, and in a range of from about 20,000 daltons to about 50,000 daltons.
  • Additional illustrative weight-average molecular weights for the polyethylene glycol polymer portion include about 200 daltons, about 300 daltons, about 400 daltons, about 500 daltons, about 600 daltons, about 700 daltons, about 750 daltons, about 800 daltons, about 900 daltons, about 1,000 daltons, about 1,500 daltons, about 2,000 daltons, about 2,200 daltons, about 2,500 daltons, about 3,000 daltons, about 4,000 daltons, about 4,400 daltons, about 4,500 daltons, about 5,000 daltons, about 5,500 daltons, about 6,000 daltons, about 7,000 daltons, about 7,500 daltons, about 8,000 daltons, about 9,000 daltons, about 10,000 daltons, about 11,000 daltons, about 12,000 daltons, about 13,000 daltons, about 14,000 daltons, about 15,000 daltons, about 20,000 daltons, about 22,500 daltons, about 25,000 daltons,
  • RSLAIL-2 may be in the form of a pharmaceutically- acceptable salt.
  • such salts are formed by reaction with a pharmaceutically- acceptable acid or an acid equivalent.
  • pharmaceutically-acceptable salt in this respect, will generally refer to the relatively non-toxic, inorganic and organic acid addition salts. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a long-acting interleukin-2 as described herein with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, oxylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, for example,
  • salts as described may be derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; or prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
  • inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic,
  • IL-2 refers to a moiety having human IL-2 activity.
  • the term,‘residue’ in the context of residue of IL-2, means the portion of the IL-2 molecule that remains following covalent attachment to a polymer such as a polyethylene glycol, at one or more covalent attachment sites, as shown in the formula above. It will be understood that when the unmodified IL-2 is attached to a polymer such as polyethylene glycol, the IL-2 is slightly altered due to the presence of one or more covalent bonds associated with linkage to the polymer(s). This slightly altered form of the IL-2 attached to another molecule is sometimes referred to a "residue" of the IL-2.
  • Proteins having an amino acid sequence corresponding to any one of SEQ ID NOs: 1 through 4 described in International Patent Publication No. WO 2012/065086 are exemplary IL-2 proteins.
  • the term substantially homologous means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences.
  • sequences having greater than 95 percent homology, equivalent biological activity (although not necessarily equivalent strength of biological activity), and equivalent expression characteristics are considered substantially homologous.
  • truncation of the mature sequence should be disregarded.
  • the IL-2 may be naturally-occurring or may be recombinantly produced.
  • the IL-2 can be derived from human sources, animal sources, and plant sources. Most preferably, the IL-2 is aldesleukin.
  • RSLAIL-2 is generally referred to as long-acting.
  • the long acting nature of an IL-2R biased agonist is typically determined using flow cytometry to measure STAT5 phosphorylation in lymphocytes at various time points after
  • the signal is lost by around 24 hours with IL-2, but is sustained for a period greater than that for a long-acting IL- 2R -biased agonist.
  • the signal is sustained over several days for (2,7-(bis- methoxyPEGiokD-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)6avginterleukin-2.
  • RSLAIL-2 possesses immunomodulating properties - in the tumor environment, RSLAIL-2 preferentially activates CD8+ effector T and natural killer (NK) cells over suppressive regulatory T cells (Tregs), such as CD4+ Tregs, by targeting CD 122 receptors found on the surfaces of cancer-fighting cells.
  • Tregs suppressive regulatory T cells
  • RSLAIL-2 also induces CD4+ T cell activation and promotes proliferation of CD4+, CD8+, and NK cells in the peripheral blood.
  • RSLAIL-2 is effective to preferentially activate and expand effector CD8+ T- and NK-cells over Tregs, it is suitable for use as a T cell expander as described herein.
  • RLSAIL-2 is provided in an IL-2R -activating amount, to thereby result in T cell expansion activity.
  • One of ordinary skill in the art can determine how much RSLAIL-2 is sufficient to provide clinically relevant agonistic activity at IL-2R .
  • the IL-2R -activating amount of RSLAIL- 2 is an amount encompassed by one or more of the following ranges expressed in amount of protein: from about 0.01 to 100 mg/kg; from about 0.01 mg/kg to about 75 mg/kg; from about 0.02 mg/kg to about 60 mg/kg; from about 0.03 mg/kg to about 50 mg/kg; from about 0.05 mg/kg to about 40 mg/kg; from about 0.05 mg/kg to about 30 mg/kg; from about 0.05 mg/kg to about 25 mg/kg; from about 0.05 mg/kg to about 15 mg/kg; from about 0.05 mg/kg to about 10 mg/kg; from about 0.05 mg/kg to about 5 mg/kg; from about 0.05 mg/kg to about 1 mg/kg.
  • Particular illustrative dosing ranges include for example, from about 0.1 mg/kg to about 10 mg/kg, or from about 0.2 mg/kg to about 7 mg/kg or from about 0.2 mg/kg to less than about
  • the IL-2R -activating amount of RSLAIL-2 is from about 0.0005 to 0.3 mg/kg; from about 0.001 mg/kg to about 0.3 mg/kg; from about 0.001 mg/kg to about 0.25 mg/kg; from about 0.001 mg/kg to about 0.15 mg/kg; from about 0.001 mg/kg to about 0.05 mg/kg; from about 0.001 mg/kg to about 0.01 mg/kg; from about 0.001 mg/kg to about 0.008 mg/kg; from about 0.001 mg/kg to about 0.005 mg/kg; from about 0.002 mg/kg to about 0.005 mg/kg; from about 0.002 mg/kg to about 0.004 mg/kg, or from about 0.003 mg/kg to about 0.006 mg/kg.
  • RSLAIL-2 is administered at a dose of about 0.006 mg/kg.
  • the amount and extent of the activation can vary widely and still be effective when coupled with administration of a neoantigen-based DNA cancer vaccine, optionally with a checkpoint inhibitor, such as an anti-PD-1 antibody, to effectively drive expansion of neoepitope-specific T cells.
  • the combination therapy may also comprise administration of an additional immunotherapeutic agent such as a checkpoint inhibitor.
  • Checkpoint inhibitors suitable for use in the method provided herein include antibodies, such as for example, monoclonal antibodies, that target PD-1, PD-L1, or CTLA-4.
  • the checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-Ll antibody.
  • exemplary PD-1 inhibitors include but are not limited to pembrolizumab, nivolumab, and cemiplimab.
  • Representative PD-L1 inhibitors include, for example, atezolizumab, avelumab, and durvalumab.
  • ipilimumab or tremelimumab anti-CTLA-4 monoclonal antibodies
  • Both are fully humanized anti-CTLA- 4 monoclonal antibodies of IgGl and IgG2, respectively.
  • a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody such as nivolumab may be administered.
  • One of ordinary skill in the art can determine how much anti-PD-1 antibody, such as nivolumab, or anti-PD-Ll antibody, is sufficient to provide clinically relevant inhibition of the PD-1 pathway or the PD-L1 pathway, respectively.
  • one of ordinary skill in the art can refer to the literature and/or administer a series of increasing amounts of nivolumab or another anti-PD-1 or anti-PD-Ll antibody to determine which amount or amounts provide clinically relevant inhibition of the PD-1 or PD-L1 pathway.
  • a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody may be administered.
  • a PD-1 pathway-inhibiting amount of the anti-PD-1 antibody is encompassed by one or more of the following ranges: from about 1 mg/kg to about 1000 mg/kg; from about 2 mg/kg to about 900 mg/kg; from about 3 mg/kg to about 800 mg/kg; from about 4 mg/kg to about 700 mg/kg; from about 5 mg/kg to about 600 mg/kg; from about 6 mg/kg to about 550 mg/kg; from about 7 mg/kg to about 500 mg/kg; from about 8 mg/kg to about 450 mg/kg; from about 9 mg/kg to about 400 mg/kg; from about 5 mg/kg to about 200 mg/kg; from about 2 mg/kg to about 150 mg/kg; from about 5 mg/kg to about 100 mg/kg; from about 10 mg/kg to about 100 mg/kg; and from about 10 mg/kg to about 60 mg/kg. Further guidance
  • an anti -PD-1 antibody such as nivolumab, or other suitable checkpoint inhibitor
  • the amount and extent of the inhibition can vary widely and can still be effective, even when combined with administration of a T cell expander and the neoantigen-based DNA cancer vaccine.
  • an amount of an anti-PD-1 antibody, i.e., nivolumab, that only minimally inhibits the PD-1 pathway can still be an inhibiting amount as used herein so long as the method results in a clinically meaningful response.
  • the actual dose to be administered, for each of the immunotherapeutic components will vary depend upon the age, weight, and general condition of the subject as well as the severity of the cancer being treated, the judgment of the health care professional, and the particular identities and properties of each of the immunotherapeutic components.
  • the subject has received one, two, three, four, five or more prior cancer treatments.
  • the subject is treatment-naive.
  • the subject has progressed on other cancer treatments.
  • the prior cancer treatment comprised an immunotherapy.
  • the prior cancer treatment comprised a chemotherapy.
  • the tumor has reoccurred.
  • the tumor is metastatic. In yet other embodiments, the tumor is not metastatic.
  • the subject has received a prior therapy to treat the tumor and the tumor is relapsed or refractory. In some embodiments, the subject has received a prior immuno-oncology therapy to treat the tumor and the tumor is relapsed or refractory. In some embodiments, the subject has received more than one prior therapy to treat the tumor and the subject is relapsed or refractory.
  • a neoantigen-based DNA cancer vaccine is first administered to generate a neoantigen-specific immune response in the subject, followed by one or more subsequent administrations of the neoantigen-based DNA cancer vaccine (induction period).
  • the subsequent administrations of the neoantigen-based DNA cancer vaccine may be administered within 1 week, 2 weeks, 3 weeks or 4 weeks or more following the first administering.
  • Non limiting parameters that indicate the treatment method is effective include any one or more of the following: tumor shrinkage (in terms of weight and/or volume); a decrease in the number of individual tumor colonies; tumor elimination; and progression-free survival. Change in tumor size may be determined by any suitable method such as imaging.
  • Various diagnostic imaging modalities can be employed, such as computed tomography (CT scan), dual energy CDT, positron emission tomography and MRI.
  • the frequency and schedule of administering the neoantigen- based DNA cancer vaccine and the T cell expander optionally combined with a checkpoint inhibitor
  • a clinician can decide to administer the neoantigen-based DNA cancer vaccine, either as a single dose or in a series of doses, e.g., over the course of several days or weeks.
  • the T cell expander is administered, either concurrently with the neoantigen-based DNA cancer vaccine, prior to vaccination, or following administration of the cancer vaccine.
  • the T cell expander e.g., RSL AIL-2
  • the T cell expander is administered following the vaccination induction period.
  • RSL AIL-2 such composition may be administered relatively infrequently (e.g., once every four weeks, once every three weeks, once every two weeks, one every 8-10 days, once every week, etc.).
  • dosing of the neoepitope-specific DNA-based cancer vaccine and the T cell expander are scheduled to align or substantially align the peak T cell responses of both therapeutic agents, to thereby achieve an optimized (and preferably synergistic) response.
  • initial administration of a T cell expander is subsequent to one or more administrations of a neoepitope- specific DNA-based cancer vaccine, and is preferably in a manner in which peak T cell responses due to administration of each immunotherapeutic agent are substantially matched, particularly following initial or early rounds of vaccination and/or administration of the T cell expander.
  • a treatment protocol includes a time period for screening and manufacture of a therapeutic neoantigen-based DNA cancer vaccine against tumor-specific neoantigens, a vaccination induction period where the anticancer vaccine is administered, and a vaccination maintenance period where a T cell expander is administered.
  • the anticancer vaccine is preferably administered one or more times concurrently with or separate from the T cell expander.
  • the anticancer vaccine may be prepared by any means as known in the art.
  • the anticancer vaccine against tumor-specific neoantigens is prepared by sequencing the genome, or exome of a tumor; identifying tumor neoantigens comprising neoepitopes from the tumor; and selecting neoepitopes based on a predicted antigenicity.
  • An exemplary method of preparing such an anticancer vaccine is described in U.S. Patent Publication No. 2019/0022202, the methods of preparation being incorporated by reference herein. After screening the tumor and manufacture of the anticancer vaccine, e.g.
  • the neoantigen-based DNA cancer vaccine against tumor-specific neoantigens and/or T cell expander are administered according to a dosing schedule or protocol that provides a peak response for one or both of the anticancer vaccine and the T cell expander.
  • the neoantigen-based DNA cancer vaccine may initially be administered for a period of time (e.g. 4-8 weeks or longer) as a vaccination induction.
  • the patient may be vaccinated one or more times with the neoantigen- based DNA cancer vaccine during the induction period.
  • the T cell expander is administered one or more times with or without administration of additional or maintenance anticancer vaccine.
  • the T cell expander and/or the neoantigen-based DNA cancer vaccine may be administered for a period of time as needed for treatment (e.g. 1-12 months or longer).
  • An exemplary administration schedule for treatment is provided below: [00153] Table 1. Exemplary Administration Schedule
  • Exemplary lengths of time associated with the course of therapy include about one week; about two weeks; about three weeks; about four weeks; about five weeks; about six weeks; about seven weeks; about eight weeks; about nine weeks; about ten weeks; about eleven weeks; about twelve weeks; about thirteen weeks; about fourteen weeks; about fifteen weeks; about sixteen weeks; about seventeen weeks; about eighteen weeks; about nineteen weeks; about twenty weeks; about twenty-one weeks; about twenty-two weeks; about twenty- three weeks; about twenty four weeks; about seven months; about eight months; about nine months; about ten months; about eleven months; about twelve months; about thirteen months; about fourteen months; about fifteen months; about sixteen months; about seventeen months; about eighteen months; about nineteen months; about twenty months; about twenty one months; about twenty-two months; about twenty-three months; about twenty-four months; about thirty months; about three years; about four years and about five years.
  • treatment methods described herein are typically continued for as long as the clinician overseeing the patient's care deems the treatment method to be effective, i.e., that the patient is responding to treatment, including no further progression of the disease, e.g., cancer.
  • Non-limiting parameters that indicate the treatment method is effective may include one or more of the following: tumor shrinkage (in terms of weight and/or volume and/or visual appearance); a decrease in the number of individual tumor colonies; tumor elimination; progression-free survival; appropriate response by a suitable tumor marker (if applicable), increased number of NK (natural killer) cells, increased number of T cells, increased number of memory T cells, increased number of central memory T cells, reduced numbers of regulatory T cells such as CD4+ Tregs, CD25+ Tregs, and FoxP3+ Tregs.
  • tumor shrinkage in terms of weight and/or volume and/or visual appearance
  • a decrease in the number of individual tumor colonies may include one or more of the following: tumor shrinkage (in terms of weight and/or volume and/or visual appearance); a decrease in the number of individual tumor colonies; tumor elimination; progression-free survival; appropriate response by a suitable tumor marker (if applicable), increased number of NK (natural killer) cells, increased number of T cells, increased number of memory T cells, increased number of central memory T cells, reduced numbers
  • patients may be responsive to the neoantigen-based DNA alone, as well as the combination with the T cell expander, optionally with a checkpoint inhibitor (CPI), but are more responsive to administration of the combination.
  • CPI checkpoint inhibitor
  • patients may be non-responsive or only marginally responsive to the neoantigen-based DNA cancer vaccine, or the T cell expander, or the checkpoint inhibitor, but are more responsive to the combination.
  • patients may be non-responsive to the neoantigen-based DNA cancer vaccine or to the T cell expander or to the checkpoint inhibitor alone, but are responsive to the combination.
  • Administration e.g., of the neoantigen-based DNA cancer vaccine and/or the T cell expander (e.g., RSLAIL-2) and/or the checkpoint inhibitor is typically via injection.
  • Other modes of administration are also contemplated, such as pulmonary, nasal, buccal, rectal, sublingual and transdermal.
  • parenteral includes subcutaneous, intravenous, intra-arterial, intratumoral, intralymphatic, intraperitoneal, intracardiac, intrathecal, and intramuscular injection, as well as infusion injections.
  • cancers such as, for example, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
  • lymphangioendotheliosarcoma synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, brain cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell cancer, basal cell cancer, adenocarcinoma, sweat gland cancer, sebaceous gland cancer, papillary cancer, papillary adenocarcinomas,
  • cystadenocarcinoma medullary cancer, bronchogenic cancer, renal cell cancer, hepatoma, bile duct cancer, choriocarcinoma, seminoma, embryonal cancer, Wilms' tumor, cervical cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, lung cancer, small cell lung cancer, brain cancer, bladder cancer, epithelial cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, multiple myeloma, neuroblastoma, retinoblastoma and leukemias.
  • the cancer to be treated is a solid cancer, such as for example, breast cancer, ovarian cancer, colon cancer, prostate cancer, bone cancer, colorectal cancer, gastric cancer, lymphoma, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and adrenocortical cancer.
  • a solid cancer such as for example, breast cancer, ovarian cancer, colon cancer, prostate cancer, bone cancer, colorectal cancer, gastric cancer, lymphoma, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and ad
  • the present methods, combinations and compositions are useful for enhancing the therapeutic effectiveness of a neoantigen-based DNA cancer vaccine, for example, by improving the subject’s immune response to the neoantigen-based DNA cancer vaccine composition.
  • An enhanced response may be evaluated at any suitable time point during treatment, after a single round of treatment, after 2-3 cycles of treatment, etc., and by any of a number of suitable methods, including shrinkage of a tumor (partial response), i.e., an evaluation of tumor size or volume, disappearance of a tumor, a reduction in disease progression (cancer has not progressed), and analysis of one or more tumor test markers if appropriate.
  • the methods, kits, compositions and the like provided herein are also useful for reducing tumor growth or size (or volume) in a subject undergoing treatment.
  • Treatment by administering a therapeutically combination as described herein is effective, in one or more embodiments, to reduce tumor growth or size in the subject.
  • one or more cycles of treatment is effective to reduce tumor size by about 25%, or by about 30%, or by about 40%, or by about 50%, or even by about 60%, or by about 70% or more when compared to the size of the tumor prior to treatment.
  • the methods, compositions and the like provided herein are effective to inhibit accumulation of regulatory T cells (Tregs) in a subject undergoing treatment for cancer.
  • the methods, compositions and the like provided herein are effective to stimulate T cell and/or NK cell activity and/or proliferation in a subject.
  • the method is effective, for example, when evaluated in a cancer mouse model of the corresponding cancer, for increasing the number of CD8+ T cells and/or CD4 T cells in the subject when compared to vaccination with a neoantigen-based DNA cancer vaccine alone.
  • the subject’s CD8+ T cells may be increased by 2-fold or more, or 3-fold or more, or even 4-fold or more, when compared to treatment with the neoantigen-based DNA cancer vaccine alone.
  • the treatment may, in some embodiments, be effective to increase the subject’s CD8+ T cells or CD4 T cells against the neoantigens by at least 2-fold or more, or 3 -fold or more, or even 4- fold or more, or 5-fold or more, or 6-fold or more when compared to an untreated subject.
  • the supporting preclinical studies provide an indication of the synergistic effect arising from the administration of a neoantigen-based DNA cancer vaccine when accompanied by administration of the exemplary T cell expander, RSLAIL-2, and optionally, a checkpoint inhibitor.
  • Example 1 As illustrated in Example 1, it was discovered that administration of the exemplary T cell expander, RSLAIL-2, in combination with an exemplary individualized anticancer DNA vaccine directed to a plurality of neoepitopes from tumor neoantigens, e.g., VB4011, is effective to not only increase the frequency, but to also increase the total numbers of neoepitope-specific T cells when evaluated in a preclinical melanoma model in mice.
  • tumor neoantigens e.g., VB4011
  • vaccination with the therapeutic neoepitope-specific DNA-based cancer vaccine is effective to induce a neoepitope-specific T cell response, which is then further expanded by administration of a T cell expander such as RSLAIL-2, effective to further expand the existing T cell population unspecifically.
  • a T cell expander such as RSLAIL-2
  • an optimized (and preferably synergistic) response could be achieved. See, for example, the results shown in FIGs.
  • T cell expander such as RSLAIL-2 subsequent to one or more administrations of a neoepitope- specific DNA-based cancer vaccine, and preferably in a manner in which peak T cell responses due to administration of each immunotherapeutic agent are substantially matched, particularly following initial or early rounds of vaccination and/or administration of the T cell expander.
  • RSLAIL-2 administration of the T cell expander
  • the timing of administration of the T cell expander, RSLAIL-2, relative to the timing of administration of a second dose of the neoepitope- specific DNA-based cancer vaccine affected the T cell response. That is to say, as shown in FIG. 5B, administration of RSLAIL-2 at a period of time following administration of a second dose of the vaccine, in this case, 3 days later, resulted in a notable enhancement of the specific T cell response.
  • FIG. 5C provides the results of administering RSLAIL-2 at various stages of the exemplary vaccination schedule, e.g., same day administration of the 3rd vaccine dose and RSLAIL-2, as well as administration of the 3 rd vaccine dose with delayed administration of RSLAIL-2. If two or more vaccinations, RSLAIL-2 administration was delayed by 3 days; in the case of a single vaccination, administration of RSLAIL-2 was delayed 7, 11 or 14 days.
  • T cell expander such as RSLAIL-2 following the neoepitope-specific DNA-based cancer vaccine induction phase (e.g., following more than one vaccination, e.g., following 2 or 3 or 4 or more vaccinations) to thereby synergize or at least maximize the specific T cell response, preferably with reduced sensitivity to timing of administration of the T cell expander.
  • T cell expander (2,7-(bis-methoxyPEGiokD-carboxyamide)(9H-fluorene-9- yl)methyl N-carbamate)6 avg interleukin-2 (“RLSAIL-2”), could boost the neoepitope-specific IFN-g T cell response when administered in combination with an exemplary T cell expander, (2,7-(bis-methoxyPEGiokD-carboxyamide)(9H-fluorene-9- yl)methyl N-carbamate)6 avg interleukin-2 (“RLSAIL-2”), could boost the neoepitope-specific IFN-g T cell response when administered in combination with an exemplary
  • VB10.NEO and the T cell expander, RSLAIL-2, significantly synergizes to boost neoepitope-specific T cells responses, resulting in up to 5-fold increase in the number of neoepitope-specific T cell responses compared to VBIO.NEO monotherapy.
  • Example 3 explores whether the T cell expander, RSLAIL-2, could increase tumor protective immune responses in VB4061 and anti-PD-1 antibody vaccinated mice (as illustrative of a subject undergoing cancer treatment with a checkpoint inhibitor further combined with administration of an individualized neoantigen-based DNA cancer vaccine) in a CT26 tumor model.
  • Treatment with VB4061 alone and in combination with anti-PD-1 induces tumor protective responses (data not shown).
  • vaccination could induce tumor protective immune responses (FIGs. 4A-4D).
  • mice vaccinated with VB4061 and anti-PD-l were further and notably boosted when administered in combination with the T cell expander, RSLAIL-2.
  • Reduced tumor growth was observed in the triple-therapy VB4061 + anti-PD-1 antibody + RSLAIL-2 treated group, where 50% of triple-treated mice remained tumor free and never did establish tumors.
  • only 20% of mice receiving VB4061 + anti-PD-1 antibody without RSLAIL-2 (FIG. 4B) were protected.
  • tumor regression of established tumors was observed, and overall survival was 70% and 80% in each of the VB4061 + anti-PD-1, and VB4061 + anti-PD-1 + RSLAIL-2 treated groups, respectively (FIG. 4C).
  • both treatment groups were fully protective against the lethal dose of CT26 cells and both groups were statistically different from the control group both in tumor growth and in overall survival.
  • RSLAIL-2 was diluted in dilution buffer to a concentration of 0.1 mg/ml and the volume determined to arrive at a final dose of 0.8 mg/kg, based upon the weight of the mouse, and injected into the tail vein of the mice.
  • RSLAIL-2 is provided as a sterile white to yellow lyophilized powder for reconstitution as described in Example 4.
  • VBIO.NEO pDNA constructs VB4011 and VB4061, were used as illustrative neoantigen- based DNA anticancer vaccines.
  • the pDNA constructs, VB4011 and VB4061 encode 10 neoepitopes from B16 and 20 neoepitopes from CT26, respectively, as described in Table 2 below. Vaccination of mice was performed in combination with electroporation.
  • FIG. 13 different functional elements of the pVBlO.NEO plasmids are shown in FIG. 13.
  • Anti-PD-1 antibody precbnical experiments: InVivoMAb anti-mouse PD- 1, Clone RMP1-14. Cat no: BE0146 (Bio X Cell®).
  • GGGGSE 10 amino acid linker
  • amino acid sequence of VB4011 corresponds to SEQ ID NO: 1 (FIG. 1).
  • the amino acid sequence of VB4061 corresponds to SEQ ID NO:2 (FIG. 8).
  • a listing of the twenty neoepitopes included in the VB4061 mouse construct is shown in FIG. 9 and correspond to SEQ ID NOs:3-22.
  • a listing of the ten individual neoepitopes included in the VB4011 construct is shown in FIG. 10 and correspond to SEQ ID NOs:23-32.
  • IFN-Y ELISpot assay Briefly, splenocytes, CD4+ or CD8+ T cell depleted splenocytes were re-suspended to a cell concentration of 6xl0 5 cells. The cells were plated in triplicates (if limited number of cells duplicates were used) and re-stimulated for 24 hours with 2 pg/ml of individual peptides corresponding to the neoepitopes in the original VB10.NEO constructs (Table 2) used during vaccination. Immunogenicity was analyzed by IFN-g ELISpot Plus kit (Mabtech AB, Sweden) following the manufacturer’s instructions.
  • SPU Spot-forming units
  • CT26 tumor cells (# CRL-2638, ATCC) were cultured in bottles with culture medium (RPMI 1640, 10 mM HEPES, 1 mM sodium pyruvate, 1% non-essential amino acid solution, 1% penicillin/streptomycin, 10% FBS). Prior to injection, the cells were washed twice in lx PBS while still adherent to the flask and then trypsin treated, washed and resuspended in lx PBS to a final concentration of 5xl0 5 cell/ml. BALB/cJRj mice were injected s.c.
  • VBIO.NEO non-replicative, non-integrating, genetically stable and non-pathogenic naked, covalently closed, circular and supercoiled double-stranded deoxyribonucleic acid (DNA) plasmid of 6297-7407 base pairs, dependent on the number of neoepitopes included in the personalized human vaccine.
  • DNA deoxyribonucleic acid
  • the DNA plasmid is based on the pUMVC4a vector backbone encoding a single recombinant homodimer protein that includes three modules: the targeting, the dimerization and the neoepitope antigenic module.
  • the targeting module encodes the human chemokine macrophage inflammatory protein- 1 alpha (hMIP-la), which binds to its cognate receptors on the cell surface of antigen presenting cells (APCs), while the dimerization module encodes the upper and lower hinge regions and the constant heavy chain 3 (CH3) domain from human IgG3.
  • the lower hinge region links two vaccibody monomers by disulfide bridges and the CH3 domain contributes to dimerization by hydrophobic interactions.
  • the upper hinge region facilitates flexible bivalent binding of the targeting module to its cognate receptors to thereby enhance the immunogenicity of the vaccine.
  • the neoepitope antigenic module consists of multiple (10-20) patient-specific neoepitopes including the somatic mutation/alteration spanning a total length of several (14 - 27) amino acids to form the neoepitope sequence and linked together by 10 amino acid flexible glycine/serine-rich linkers.
  • the glycine/serine rich linkers typically change from construct to construct for the individualized vaccines based upon an evaluation of junctional sequences, such that a selected linker will typically excludes a junctional epitope that resembles a sequence found in the human schooleome.
  • the neoepitope antigenic module is linked to the natural human chemokine macrophage inflammatory protein- la (targeting module) via a dimerization module derived from human IgG3 as described above.
  • the transcript is translated to a 603-973 amino acid-containing protein of approximately 100 kDa, which forms an approximately 200 kDa dimeric protein.
  • pVBlO. NEO Once delivered by i.m. administration to a patient, pVBlO. NEO is taken up by cells and leads to local and transient production, and secretion of the VBIO.NEO protein.
  • the structure of the encoded protein is designed and selected to support the induction of strong cellular immune responses against patient-specific neoantigens.
  • the pVBlO.NEO DNA backbone sequence (with a general indicator for the neoepitope antigenic module) is shown in FIG. 12 and provided as SEQ ID NO: 77.
  • the different functional elements of the pVBlO.NEO plasmids are shown in FIG. 13.
  • T cell expander (2,7-(bis- methoxyPEGiokD-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)6avginterleukin-2
  • VB10.NEO an exemplary immunotherapeutic DNA-based neoantigen vaccine
  • B16 model C56B1/6 mice were vaccinated 3x at day 0, 21 and 35 with either
  • ELISpot Results in the B16 Melanoma Mouse Model Administration of RSLAIL-2 in combination with VB4011 was effective to boost neoepitope-specific IFN-g T cell responses as shown in FIG. 2A and Table 4).
  • the neoepitopes M2, M3, M4, M7, M9 and M10 were immunogenic (Table 4 (immunogenic responses shown in grey boxes) and FIG. 2A).
  • the neoepitopes M2, M4, M6, M7, M9 and M10 were immunogenic.
  • a stronger immune response was observed in mice treated with the VB4011 + RSLAIL-2 combination therapy compared to VB4011 monotherapy.
  • the criterium for an immunogenic epitope was defined as >25 IFN-g + spots/10 6 cells and > IFN-g + spots/10 6 cells than average negative control (pDNA VB1026) +2xSD. However, in this experiment since splenocytes were pooled (5 mice), 2xSD could not be used.
  • the numbers represent average of triplicates in ELISpot and are presented as SPU/10 6 splenocytes. The average number of SPU in the medium control was subtracted from the average SPU elicited against each neoepitope. Wells with spot count ⁇ 0 are
  • Criteria of an immunogenic epitope was defined as >25 SPU/10 6 cells.
  • Epitopes determined to be immunogenic are boxed in grey.
  • neoepitope-specific T cells increased in mice treated with RSLAIL-2 + VB4011 (doublet). In the doublet-treated mice, it was observed that spleens were enlarged typically 2-3-fold when compared to VB4011 vaccinated mice (Table 5). Thus, in mice treated with the VB4011 - RSLAIL-2 combination, the total number of neoepitope-specific T cells also increased. To accommodate this increase, the total number of IFN-g + secreting T cells (SPU) per spleen was calculated (Table 5), and as a result, a 3.7-fold increase of neoepitope-specific T cells was determined (see also FIG. 2B). This increase was evident for both CD8+ T cells and
  • CD4+ T cells (FIGs. 2C and 2D, respectively). This finding demonstrates that administration of RSLAIL-2 in combination with VB4011 is effective to not only increase the frequency, but to also increase the total numbers of neoepitope-specific T cells in a preclinical melanoma model in mice.
  • a neoepitope specific T vaccine-induced T cell response that is, following vaccination (i.e., of a first, second, or subsequent dose of the vaccine).
  • vaccination with the therapeutic neoepitope-specific DNA-based cancer vaccine is effective to induce a neoepitope-specific T cell response, which is then further expanded by administration of a T cell expander such as RSLAIL-2, effective to further expand the existing T cell population unspecifically.
  • a T cell expander such as RSLAIL-2
  • FIGs. 5A and 5B which support, based upon this preclinical cancer model, administration of a T cell expander such as RSLAIL-2 subsequent to one or more administrations of a neoepitope-specific DNA-based cancer vaccine, and preferably in a manner in which peak T cell responses due to administration of each immunotherapeutic agent are substantially matched, particularly following initial or early rounds of vaccination and/or administration of the T cell expander.
  • a T cell expander such as RSLAIL-2 subsequent to one or more administrations of a neoepitope-specific DNA-based cancer vaccine
  • peak T cell responses due to administration of each immunotherapeutic agent are substantially matched, particularly following initial or early rounds of vaccination and/or administration of the T cell expander.
  • an optimal response was observed when administration of the T cell expander, RSLAIL-2, occurred 11 days following administration of the vaccine.
  • FIG. 5C provides the results of administering RSLAIL-2 at various stages of the vaccination schedule, e.g., same day administration of the 3rd vaccine dose and RSLAIL-2, as well as administration of the 3 rd vaccine dose with delayed administration of RSLAIL-2. If two or more vaccinations, RSLAIL-2 administration was delayed by 3 days; in the case of a single vaccination, administration of RSLAIL-2 was delayed 7, 11 or 14 days. Based upon these results in the B16 model, it appears that administration of the T cell expander, RSLAIL-2, with a second dose of the vaccine modestly synergizes the specific T cell response, and that in this same model, administration of RSLAIL-2 with the 3 rd dose of vaccine does appear to
  • T cell expander such as RSLAIL-2 following the neoepitope-specific DNA- based cancer vaccine induction phase (e.g., following more than one vaccination, e.g.,
  • T cell expander (2,7-(bis- methoxyPEGiokD-carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate)6 avg interleukin-2
  • VBIO.NEO immunotherapeutic DNA-based neoantigen vaccine
  • CT26 model In the CT26 model, BALB/c mice were vaccinated lx with either 50 pg control pDNA VB1026 or 50 pg VB4061. RSLAIL-2 (0.8 mg/kg) was
  • mice pDNA 50 mg ELISpot tumor cells 0.8 mg/kg
  • Day 0 VB4061 day 7 Day 14 Day 21 may also consider tumor day as occurring on day (-)7, vaccination occurring on day 0 and administration of RSLAIL-2 on day 7. [00197] Other vaccination/administration schedules were also explored.
  • ELISpot in CT26 colon cancer model In line with the strong synergism observed in the exemplary B16 melanoma model described in Example 1 above, the neoepitope-specific IFN-g T cell responses were also significantly elevated for the combination of VB4061 and RSLAIL-2 in the CT26 mouse tumor model (FIGs. 3A-3D and Table 7).
  • mice vaccinated with VB4061 immune responses against the neoepitopes Ml, M30, Ml 03 and Ml 06 were elicited (FIG. 3A and Table 7, immunogenic epitopes are indicated in grey boxes).
  • mice treated with VB4061 + RSLAIL-2 6 more neoepitopes induced immune responses (M2, M8, M65, Ml 12 and Ml 25).
  • the splenocytes isolated from RSLAIL-2 monotherapy-treated mice elicited immune responses only against the neoepitope Ml 12.
  • Splenocytes of individual mice were analyzed in the ELISpot assay and the criteria for an immunogenic epitope was defined to be >25 IFN-g + spots/10 6 cells and > average negative control (VB1026) +2xSD (Table 7, the numbers of average negative control (VB1026+2xSD) are shadowed in the second column.
  • the numbers represent duplicates of individual mice in ELISpot and presented as SPU/10 6 splenocytes.
  • the average number of SPU in the medium control was subtracted from the average of SPU elicited against each neoepitope for each sample. Samples with spot counts ⁇ 0 are reported as 0.
  • An immunogenic epitope is defined as>25 SPU/10 6 splenocytes and > average negative control (VB1026) +2xSD. Epitopes deemed immunogenic are indicated by a grey box.
  • mice treated with RSLAIL-2 were treated with RSLAIL-2.
  • IFN-g + secreting T cells per spleen was calculated.
  • a 4-fold increase in total number of neoepitope-specific T cells was observed in RSLAIL-2 + VB4061 treated mice (FIG. 3B).
  • lymphocytes such as NK and effector CD8+ T cells above CD4+ T cells, due to their
  • exemplary neoepitope cancer vaccine VB10.NEO, and RSLAIL-2 significantly synergizes to boost neoepitope-specific T cells responses, resulting in up to 5-fold increase in the number of neoepitope-specific T cell responses compared to VB10.NEO monotherapy. Mice treated with VB10.NEO in combination with RSLAIL-2 exhibited a stronger response to each
  • neoepitope and also to more neoepitopes, demonstrating that the combination increased both the breadth and depth of the immune response.
  • both frequency and total number of neoepitope-specific T cells were elevated.
  • the synergistic effect was even more profound on the CD8+ T cell responses compared with CD4+ T cell responses supporting the combination’s ability to induce strong neoepitope-specific CD8+ T cell responses.
  • VB4061 encodes 20 neoepitopes from CT26 as shown above in Table 2 above and in FIGs. 7 and 8.
  • mice All Balb/c mice were challenged with a lethal dose of 5xl0 4 CT26 tumor cells at day 0. 50 pg VB4061 was administered intramuscularly (i.m.) with electroporation at day 0, 3, 7, 10, 14, 27 and 64. 200 pg of an anti-PD-1 antibody was injected intraperitoneally
  • VB4061 alone and in combination with anti-PD-1 induces tumor protective responses (data not shown).
  • vaccination could induce tumor protective immune responses (FIGs. 4A-4D).
  • the results of this experiment illustrate that tumor protection in mice vaccinated with VB4061 and anti-PD-1 was further boosted when administered in combination with RSLAIL-2. Tumor growth, tumor take and overall survival are shown in FIGs. 4A-4C.
  • Re-challenge The Balb/c mice in both treatment arms that were tumor-free on day 56 were re-challenged with a second lethal dose of 5xl0 4 CT26 tumor cells without further treatment.
  • FIG. 7A-7B Tumor length for untreated mice (control) and mice treated with VB4061 + anti-PD-1 + RSLAIL-2 groups was further monitored regularly by measuring the tumor length size (mm) using an electronic caliper. In this study, it was confirmed that vaccination could induce tumor regression and stabilization in a CT26 colon carcinoma mouse model (FIGs. 7A-7B).
  • the results of this experiment illustrate that tumor protection in mice vaccinated with VB4061 and anti-PD-1 was further boosted when administered in combination with RSLAIL-2.
  • Fig. 7B vaccination of mice with VB4061 and anti-PD-1 in combination with administration of RSLAIL-2 resulted in rapid, complete and long lasting tumor regression in mice with relatively small tumors (e.g. tumors less than about 5-6 mm) as well as long lasting stabilization of larger tumors (e.g. tumors larger than about 5-6 mm and even larger than about 10 mm).
  • Objectives The primary objective of this Phase l/2a study is to assess the safety/tolerability of (i) multiple doses of 3 mg VB10.NEO immunotherapy and of (ii) multiple doses of 3 mg VB10.NEO immunotherapy in combination with 0.006 mg/kg RSLAIL-2. Secondary objectives include (i) assessment of the immunogenicity of multiple doses of 3 mg VB10.NEO immunotherapy and of multiple doses of 3 mg VB10.NEO immunotherapy in combination with 0.006 mg/kg RSLAIL-2, and (ii) additional preliminary assessments of the efficacy of multiple doses of 3 mg VB10.NEO immunotherapy and of multiple doses of 3 mg VB10.NEO immunotherapy in combination with 0.006 mg/kg RSLAIL-2.
  • Additional exploratory objects include, for example, an investigation of the immune signature alterations during therapy, and exploration of the correlation between immunological response and clinical efficacy after VB10.NEO immunotherapy alone or in combination with RSLAIL-2.
  • Rationale Pre-clinical studies (above) have shown that the combination of VBIO.NEO and RSL AIL-2 synergizes to boost neoepitope-specific T cells responses, resulting in a 5-fold increase in the number of neoepitope-specific T cell responses compared to VBIO.NEO alone.
  • mice treated with VBIO.NEO in combination with RSLAIL-2 showed both a stronger response to each neoepitope and to increased numbers of neoepitopes, showing that both the breadth and depth of the immune response were elevated.
  • the combination showed an even more evident effect on CD8+ T cell responses as the combination elicited a neoepitope-specific CD8+ T cell response to more neoepitopes compared to either drug when administrated alone, further strengthening the combination’s ability to induce strong neoepitope-specific CD8+ T cell responses.
  • this open-label first-in-human phase l/2a study is designed to evaluate the safety and efficacy of multiple dosing with individualised VBIO.NEO or VBIO.NEO and RSLAIL- 2 immunotherapy in combination, in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC (non-small cell lung cancer), clear-cell RCC (renal cell cancer), urothelial cancer or SCCHN (squamous cell carcinoma of the head and neck), who did not reach complete responses with current standard of care (i.e., checkpoint inhibitor therapy, CPI).
  • CPI standard of care includes, e.g., nivolumab, pembrolizumab or atezolizumab. This study protocol may be amended during the course of the study.
  • Part A of the study consists of 6 arms in 5 different tumor entities. All patients are administered VBIO.NEO on the background of CPI therapy. Patients receive CPI at least from the commencement of vaccine manufacturing (arms 1, 5 A and 5B) or for additional > 12 weeks (arms 2-4). Arm 5 (SCCHN) is divided into arm 5 A and arm 5B. Arm 5 A is administered VBIO.NEO whereas arm 5B receives the combination of VBIO.NEO and RSLAIL-2.
  • Part B of the study will be opened after a certain number of patients have been enrolled and analysed in part A.
  • the expansion part B will include up to 3 tumor-specific expansion cohorts.
  • the study is divided into 3 periods: a screening and manufacturing period, a treatment period, and a long-term follow-up period.
  • the neoantigenic vaccine is a non-replicative, non-integrating, genetically stable and non-pathogenic naked, covalently closed, circular and supercoiled double-stranded deoxyribonucleic acid (DNA) plasmid of 6297-7407 base pairs, dependent on the number of neoepitopes included in the personalized vaccine. It encodes a single recombinant homodimer protein consisting of 3 modules: the targeting, the dimerization and the neoepitope antigenic module.
  • DNA deoxyribonucleic acid
  • the latter consists of multiple (10-20) patient-specific neoepitopes including the somatic mutation/alteration spanning a total length of several (14 - 27) amino acids to form the neoepitope sequence and linked together by 10 amino acid flexible glycine/serine-rich linkers.
  • the neoepitope antigenic module is linked to the natural human chemokine macrophage inflammatory protein- la (targeting module) via a dimerization module derived from human IgG3.
  • the transcript is translated to a 603-973 amino acid-containing protein of approximately 100 kDa, which forms an approximately 200 kDa dimeric protein. See FIG. 12.
  • the glycine/serine-rich linkers used between the neoepitopes typically change from construct to construct for the different patient vaccines based upon evaluation of junctional sequences such that a preferred linker is one that excludes a junctional epitope that resembles a sequence found in the human genome.
  • Illustrative linkers that may be used between the neoepitopes include those provided in SEQ ID NOs:67-76.
  • VBIO.NEO Screening, manufacturing, and delivery of VBIO.NEO vaccine: VBIO.NEO is supplied as a sterile, ready to use solution at a concentration of 3 mg/mL in phosphate buffered saline pH 7.4 in 2 mL sterile cyclo-olefin copolymer vials. The vials are stored at - 20°C ( ⁇ 5°C). The vaccine is administered using a needle-free injection system,
  • neoepitopes are selected based on qualified algorithms identifying immunogenic neoepitopes with low risk of inducing autoimmunity.
  • the individual VBIO.NEO vaccine is then synthesized; it is estimated that the process from tumor sampling to administration will take approximately 12 to 16 weeks, preferably from 6-10 weeks, and more preferably from 4-6 weeks.
  • the vaccinations are given by intramuscular injection.
  • Arm 1-4 Patients screened must have been receiving for at least 12 weeks a checkpoint inhibitor (anti-PD-1 or anti-PD-Ll) as the patient’s standard of care and according to currently approved indications.
  • a checkpoint inhibitor anti-PD-1 or anti-PD-Ll
  • Arms 5 A and 5B Patients can be screened as long as CPI treatments have been started as the patient’s standard of care for SCCHN.
  • eligible patients provide a blood sample and at least 1 tumor specimen.
  • the blood sample and the tumor specimen are mandatory. Once an adequate tumor specimen is available, the patient is enrolled, and the individualized neoantigen vaccine manufacturing period starts (approximately 12-16 weeks).
  • the blood and tissue samples are included into the exome-sequencing program where the exome sequenced from the blood and the tumor sample/s are compared to identify the patients’ individual somatic tumor-specific mutations (neoepitopes).
  • the blood and tissue samples are included into the exome-sequencing program where the exome sequenced from the blood and the screening tumor sample/s are compared to identify the patient’s individual somatic tumor-specific mutations (neoepitopes).
  • Neoepitopes found in more than one sample fresh biopsies, available archival tumor specimens and cell free (cf)DNA from blood
  • the tumor samples are subjected to RNA sequencing to select neoepitopes found in expressed proteins in the tumor.
  • the blood sample is used for HLA typing to select neoepitopes that bind the individual patient’s HLA molecules.
  • Vaccinations with individualized VBIO.NEO immunotherapy are commenced as soon as the patient- specific VBIO.NEO vaccine is available and if the patient-specific vaccine meets all pre specified product-release criteria after manufacturing.
  • RSLAIL-2 provided as a lyophilized powder, is reconstituted by the clinician prior to administration, and each patient’s dose is determined by the patient’s weight in kilograms. RSLAIL-2 is administered IV over 30 ( ⁇ 5) minutes at a starting dose of
  • RSLAIL-2 is administered on the same day as VBIO.NEO.
  • the vaccination occurs first, and the RSLAIL- 2 administration occurs 2 hours later. If treatment with CPI occurs on the same day, then the dosing is in the following order with the time interval between: (1) VBIO.NEO (wait 2 hours); (2) RSLAIL-2 (wait 30 minutes) (3) CPI.
  • RSLAIL-2 Dose delays and reductions are permitted for RSLAIL-2. Administration of RSLAIL-2 may be delayed or the dose reduced to 0.003 mg/kg based on observed drug-related toxicities. If the RSLAIL-2 dose is reduced to 0.003 mg/kg, the dose level should remain at this level throughout the remainder of the study.
  • Vaccinations start at visit 1. Patients will have received CPI at least from the start of manufacturing (arms 5 A and 5B) or for additional > 12 weeks (arms 1-4).
  • Patients receive a maximum of 14 vaccinations of each 3 mg VBIO.NEO at pre-specified time points for up to 1 year from first vaccination in addition to CPI.
  • the VBIO.NEO vaccine is added to this continuing CPI treatment and will not replace, omit, postpone or terminate the standard therapy.
  • patients receive 3 vaccinations of 3 mg VBIO.NEO Q3W in addition to their CPI. From week 10, patients will receive maintenance treatment with vaccinations Q4W for up to 1 year from the first vaccination in addition to their CPI.
  • RSLAIL-2 (arm 5B): Dosing with RSLAIL-2 starts at week 11 (visit 8A), 1 week after the fourth VBIO.NEO vaccination and when VBIO.NEO is expected to have created a robust neoantigen-specific T cell response. Patients with SCCHN who are enrolled into arm 5A can, if willing to and fulfil all inclusion criteria for arm 5B, move into arm 5B (upon investigator’s and sponsor’s agreement) and start treatment with RSLAIL-2 at week 11 or 1 week after any later VBIO.NEO vaccination visit in the maintenance period up to week 34 (i.e. VBIO.NEO dose 10, week 18 + 1 week). Patients who have received at least 1 dose of VBIO.NEO vaccination are eligible for RSLAIL-2 administration.
  • VBIO.NEO VBIO.NEO and CPI.
  • the first 2 doses of RSLAIL-2 4 are administered in a Q3W interval and following doses in Q4W intervals. Treatment continues until end of treatment (EoT) at visit 18 (week 50). Depending on the time point of the RSLAIL-2 start, patients receive a maximum of 11 doses of RSLAIL-2. Except for the first RSLAIL-2 dose, all following doses are administrated on the same day as VBIO.NEO.
  • Arms 1-4 To capture changes between screening and the first VBIO.NEO vaccination as well as in response to VBIO.NEO vaccination, up to 3 biopsies are taken at visit 1 (first VBIO.NEO vaccination) and 1 biopsy at visit 10 (week 18). This leads to a total maximum of 10 biopsies (3 at screening, 3 at visit 1, 1 at visit 10, and up to 3 additional biopsies at any timepoint after the first vaccination).
  • Arms 5A and 5B To characterize changes before and after RSLAIL-2 administration, patients are asked to provide optional biopsies within 7 days prior and 15-21 days after the first administration of RSLAIL-2. In addition, biopsies can be taken at visit 1. At each of these time points, up to 3 biopsies are taken. This leads to a total maximum of 13 biopsies (3 at screening, 3 at visit 1, 3 at 1 week prior to the first RSLAIL-2 dose, 3 at 15-21 days after the first administration, and 1 additional biopsy at any timepoint after the first vaccination).
  • tumor material is be secured for further analysis.
  • PBMC peripheral blood monocytic cell
  • PBMC peripheral neoepitope-specific T cell responses induced by the T cell expander, RSLAIL-2.
  • VB10.NEO vaccination (visit 7A/week 7) and 7 days after first RSLAIL-2 administration (visit 8B/week 12) in order to fine characterize neoepitope-specific T cells.
  • Functional analyses may include, for example, flow cytometry, ELISpot, enzyme-linked immunosorbent assay, and cytotox assays and will be compared with T cell clones isolated from tumor tissue/specimens.
  • Efficacy to treatment is assessed as follows. Tumor response to VB10.NEO and RSLAIL-2 is assessed by means of iRECIST at regular intervals according to standard of practice. The imaging procedure is performed as part of the standard patient care and the patient is not exposed to any further radiation due to participation in this study.
  • the imaging performed within 4 weeks of visit 1 is the baseline for tumor assessments according to iRECIST.
  • an imaging assessment should preferably be carried out as close as possible prior to the first dose of RSLAIL-2.
  • the same method of assessment (imaging modality, e.g., MRI or CT) is ideally be used to characterise each identified and reported lesion at baseline and during all follow-up examinations for an individual patient according to the individual site's practices of standard of care.
  • imaging modality e.g., MRI or CT
  • Efficacy analysis Early signs of efficacy of VB10.NEO immunotherapy alone or in combination with RSLAIL-2 will be based on Overall Response Rate (ORR), Duration of response (DOR), Progression-free survival (PFS), Overall survival (OS).
  • ORR Overall Response Rate
  • DOR Duration of response
  • PFS Progression-free survival
  • OS Overall survival
  • Efficacy analyses will be done separately for each tumor entity-specific cohort in part A and part B.
  • the efficacy endpoints will be analyzed descriptively including 95% confidence intervals for proportions wherever applicable.
  • the DOR, PFS and OS will be analyzed using the Kaplan-Meier product-limit method.
  • Additional assessments to be conducted include vital signs (body temperature, oxygenation, pulse rate, and systolic and diastolic BP, monitoring of BP, pulse and ECG, as well as blood assessments.
  • Blood analysis includes the following: differential leukocyte analysis, haemoglobin, haematocrit, red blood cell count, platelet count, urea, calcium, chloride, phosphorus-inorganic, potassium, sodium, creatinine, uric acid, C-reactive protein, ALT, AST, gamma glutamyltransferase, bilirubin, lipase, alkaline phosphatase, lactate dehydrogenase, thyroid stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), glucose, protein, albumin, partial thromboplastin time, international normalized ratio, cholesterol, triglycerides, cholinesterase, creatine kinase. Serum will also be
  • the peripheral immune response of the individualized VBIO.NEO vaccine strategy will be measured by IFN-g enzyme-linked immunospot assay (ELISpot), a surrogate for T cell activity.
  • IFN-g enzyme-linked immunospot assay a surrogate for T cell activity.
  • the immune response to each neoepitope included in the vaccines will be assessed individually.
  • further analysis may be performed by flow cytometry analysis of cellular surface markers, tetramer analysis and intracellular cytokine staining to characterize the T cell profile.
  • TCR T cell receptor

Abstract

La présente invention concerne des méthodes, associations et compositions pour le traitement d'un patient atteint de cancer par l'administration au patient d'un vaccin individualisé contre le cancer, à base d'ADN de néo-antigène, en combinaison avec un composé stimulant la croissance des cellules T ("agent stimulateur de cellules T"), c'est-à-dire un composé capable de stimuler une expansion clonale de cellules T spécifiques des épitopes du vaccin, et éventuellement combiné également à un inhibiteur de point de contrôle.
EP20763489.0A 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer Withdrawn EP3930747A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962811459P 2019-02-27 2019-02-27
US201962825487P 2019-03-28 2019-03-28
US201962838180P 2019-04-24 2019-04-24
US201962881832P 2019-08-01 2019-08-01
PCT/US2020/020224 WO2020176797A1 (fr) 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP3930747A1 true EP3930747A1 (fr) 2022-01-05
EP3930747A4 EP3930747A4 (fr) 2023-04-05

Family

ID=72238533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20763489.0A Withdrawn EP3930747A4 (fr) 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP3930747A4 (fr)
JP (1) JP2022521792A (fr)
CN (1) CN113631185A (fr)
WO (1) WO2020176797A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230005962A (ko) 2020-05-01 2023-01-10 니코데 테라퓨틱스 에이에스에이 베타코로나바이러스 예방 및 치료요법
AU2022244191A1 (en) 2021-03-26 2023-09-28 Genentech Inc. Therapeutic combination for treating cancer
WO2022233851A1 (fr) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Constructions immunogènes et vaccins destinés à être utilisés dans le traitement prophylactique et thérapeutique de maladies infectieuses
KR20240007235A (ko) 2021-05-10 2024-01-16 니코데 테라퓨틱스 에이에스에이 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도
WO2022238381A2 (fr) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Constructions d'immunothérapie pour le traitement d'une maladie
JP2024518463A (ja) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物及び免疫阻害化合物の共発現
JP2024516882A (ja) 2021-05-10 2024-04-17 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物と免疫刺激性化合物の共発現
JP2024516893A (ja) 2021-05-10 2024-04-17 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 寛容誘導構築物及び組成物並びに免疫障害の処置のためのそれらの使用
WO2022238363A1 (fr) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Constructions immunogènes et vaccins destinés à être utilisés dans le traitement prophylactique et thérapeutique de maladies infectieuses
AU2022381515A1 (en) 2021-11-03 2024-05-09 Adaptive Biotechnologies Corporation Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (fr) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructions et leur utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216403A1 (en) * 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
MA43362A (fr) * 2015-05-26 2018-10-10 Advaxis Inc Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations
KR20180100659A (ko) * 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
KR20180129899A (ko) * 2016-03-31 2018-12-05 네온 테라퓨틱스, 인크. 신생항원 및 이것의 사용 방법
US11875877B2 (en) * 2016-08-25 2024-01-16 Nantomics, Llc Immunotherapy markers and uses therefor
EP3538130A4 (fr) * 2016-11-10 2020-06-03 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
IL271558B2 (en) * 2017-06-21 2024-01-01 Transgene A vaccine tailored to the individual

Also Published As

Publication number Publication date
EP3930747A4 (fr) 2023-04-05
WO2020176797A1 (fr) 2020-09-03
CN113631185A (zh) 2021-11-09
JP2022521792A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
EP3930747A1 (fr) Association d'immunothérapies pour le traitement du cancer
US20200368321A1 (en) Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody
US20190275133A1 (en) Immunotherapeutic tumor treatment method
US11318164B2 (en) Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
JP2019505512A (ja) 治療用抗癌ネオエピトープワクチン
JP2013028619A (ja) 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US20210154277A1 (en) Immunotherapeutic combination for treating cancer
US20200317784A1 (en) Methods and compositions for treating cancer by modifying multiple arms of the immune system
US9920378B2 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
KR20210090203A (ko) 또 다른 약리학적 활성제와 조합된 지속 작용성 인터류킨-15 수용체 효현제
US20180128833A1 (en) Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto
KR20140131925A (ko) 자가 암 세포 백신
JP2022130623A (ja) がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NYKODE THERAPEUTICS ASA

Owner name: NEKTAR THERAPEUTICS

A4 Supplementary search report drawn up and despatched

Effective date: 20230306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230228BHEP

Ipc: C12N 7/00 20060101ALI20230228BHEP

Ipc: C07K 16/28 20060101ALI20230228BHEP

Ipc: A61K 39/00 20060101AFI20230228BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231003